HRP20170285T1 - Heterociklilamini kao inhibitori pi3k - Google Patents
Heterociklilamini kao inhibitori pi3k Download PDFInfo
- Publication number
- HRP20170285T1 HRP20170285T1 HRP20170285TT HRP20170285T HRP20170285T1 HR P20170285 T1 HRP20170285 T1 HR P20170285T1 HR P20170285T T HRP20170285T T HR P20170285TT HR P20170285 T HRP20170285 T HR P20170285T HR P20170285 T1 HRP20170285 T1 HR P20170285T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- pyrazolo
- pyrimidin
- amino
- methyl
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims 66
- 150000002367 halogens Chemical class 0.000 claims 64
- 150000001875 compounds Chemical class 0.000 claims 60
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 55
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 51
- 150000003839 salts Chemical class 0.000 claims 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 38
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 34
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 29
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 26
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 23
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- -1 aminosulfonylamino Chemical group 0.000 claims 19
- 125000006601 (C1-C3) alkylcarbamyl group Chemical group 0.000 claims 18
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 18
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 150000003254 radicals Chemical group 0.000 claims 11
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 10
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 10
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 9
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 102000038030 PI3Ks Human genes 0.000 claims 5
- 108091007960 PI3Ks Proteins 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 101100240985 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nrc-2 gene Proteins 0.000 claims 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- CJNJLCYTPKHVSM-YNODCEANSA-N (2r)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]propan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C[C@@H](C)O)C1 CJNJLCYTPKHVSM-YNODCEANSA-N 0.000 claims 2
- WSJWSMDGJQMOSH-AMGKYWFPSA-N (2s)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C[C@H](C)O)C1 WSJWSMDGJQMOSH-AMGKYWFPSA-N 0.000 claims 2
- NENZZUFAAHFIPT-BXKDBHETSA-N (5S)-5-[3-[(1R)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]-1,3-oxazolidin-2-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C)[C@H](C)C=1C(=C(C(=C(C=1)Cl)F)[C@H]1CNC(O1)=O)OCC NENZZUFAAHFIPT-BXKDBHETSA-N 0.000 claims 2
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 claims 2
- 125000006603 (C1-C3) alkylaminosulfonyl group Chemical group 0.000 claims 2
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims 2
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims 2
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 2
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 2
- VJJSELYTDOGDNE-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)-n-methylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)CCO)=C1 VJJSELYTDOGDNE-UHFFFAOYSA-N 0.000 claims 2
- SALBXLRGOLXPQY-AMGKYWFPSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]-4-methoxy-2-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(C[C@H](C)O)C1 SALBXLRGOLXPQY-AMGKYWFPSA-N 0.000 claims 2
- CEECNMYKERBUGO-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 CEECNMYKERBUGO-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 101100310920 Caenorhabditis elegans sra-2 gene Proteins 0.000 claims 2
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 claims 2
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 201000000498 stomach carcinoma Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- WSJWSMDGJQMOSH-JTDNENJMSA-N (2r)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C[C@@H](C)O)C1 WSJWSMDGJQMOSH-JTDNENJMSA-N 0.000 claims 1
- RJWNXJAXIOIPGQ-ARLHGKGLSA-N (2r)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]-2-hydroxypropan-1-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(=O)[C@@H](C)O)C1 RJWNXJAXIOIPGQ-ARLHGKGLSA-N 0.000 claims 1
- FBRKRAOGHVCFCB-KEKZHRQWSA-N (2r)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C[C@@H](C)O)C1 FBRKRAOGHVCFCB-KEKZHRQWSA-N 0.000 claims 1
- GAKDFKQPUPMQJG-ZGTCLIOFSA-N (2r)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-2-hydroxypropan-1-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(=O)[C@@H](C)O)C1 GAKDFKQPUPMQJG-ZGTCLIOFSA-N 0.000 claims 1
- GECCYCCZNPQZQM-NFJWQWPMSA-N (2r)-1-[3-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C[C@@H](C)O)C1 GECCYCCZNPQZQM-NFJWQWPMSA-N 0.000 claims 1
- UBGGPHDJPPNZSA-RWANSRKNSA-N (2r)-1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]propan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(C[C@@H](C)O)C1 UBGGPHDJPPNZSA-RWANSRKNSA-N 0.000 claims 1
- QKFMWXFSQKPVRN-RWANSRKNSA-N (2r)-1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-fluoro-6-methoxyphenyl]azetidin-1-yl]propan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C[C@@H](C)O)C1 QKFMWXFSQKPVRN-RWANSRKNSA-N 0.000 claims 1
- NNRGDBFNOMUWIU-ARLHGKGLSA-N (2r)-2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-n-methylpropanamide Chemical compound C1N([C@H](C)C(=O)NC)CC1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC NNRGDBFNOMUWIU-ARLHGKGLSA-N 0.000 claims 1
- FXHJMVGKCZMISA-YNODCEANSA-N (2r)-2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]propan-1-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN([C@H](C)CO)C1 FXHJMVGKCZMISA-YNODCEANSA-N 0.000 claims 1
- GMDNBZXUPFSLSL-ZGTCLIOFSA-N (2r)-2-[3-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-cyano-2-methoxy-6-methylphenyl]azetidin-1-yl]-n-methylpropanamide Chemical compound C1N([C@H](C)C(=O)NC)CC1C1=C(C)C(C#N)=CC(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)=C1OC GMDNBZXUPFSLSL-ZGTCLIOFSA-N 0.000 claims 1
- ZTUGTNZSYGNOFE-PVQCJRHBSA-N (2r)-3-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-1,1,1-trifluoropropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C[C@@H](O)C(F)(F)F)C1 ZTUGTNZSYGNOFE-PVQCJRHBSA-N 0.000 claims 1
- RJWNXJAXIOIPGQ-KZUDCZAMSA-N (2s)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]-2-hydroxypropan-1-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(=O)[C@H](C)O)C1 RJWNXJAXIOIPGQ-KZUDCZAMSA-N 0.000 claims 1
- FBRKRAOGHVCFCB-SFVWDYPZSA-N (2s)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C[C@H](C)O)C1 FBRKRAOGHVCFCB-SFVWDYPZSA-N 0.000 claims 1
- GAKDFKQPUPMQJG-ABLWVSNPSA-N (2s)-1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-2-hydroxypropan-1-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(=O)[C@H](C)O)C1 GAKDFKQPUPMQJG-ABLWVSNPSA-N 0.000 claims 1
- GECCYCCZNPQZQM-VUWPPUDQSA-N (2s)-1-[3-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]propan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C[C@H](C)O)C1 GECCYCCZNPQZQM-VUWPPUDQSA-N 0.000 claims 1
- UBGGPHDJPPNZSA-NUHJPDEHSA-N (2s)-1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]propan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(C[C@H](C)O)C1 UBGGPHDJPPNZSA-NUHJPDEHSA-N 0.000 claims 1
- QKFMWXFSQKPVRN-NUHJPDEHSA-N (2s)-1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-fluoro-6-methoxyphenyl]azetidin-1-yl]propan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C[C@H](C)O)C1 QKFMWXFSQKPVRN-NUHJPDEHSA-N 0.000 claims 1
- FXHJMVGKCZMISA-ZSOXZCCMSA-N (2s)-2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]propan-1-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN([C@@H](C)CO)C1 FXHJMVGKCZMISA-ZSOXZCCMSA-N 0.000 claims 1
- GMDNBZXUPFSLSL-ABLWVSNPSA-N (2s)-2-[3-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-cyano-2-methoxy-6-methylphenyl]azetidin-1-yl]-n-methylpropanamide Chemical compound C1N([C@@H](C)C(=O)NC)CC1C1=C(C)C(C#N)=CC(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)=C1OC GMDNBZXUPFSLSL-ABLWVSNPSA-N 0.000 claims 1
- ZTUGTNZSYGNOFE-INSVYWFGSA-N (2s)-3-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-1,1,1-trifluoropropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C[C@H](O)C(F)(F)F)C1 ZTUGTNZSYGNOFE-INSVYWFGSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-MNOVXSKESA-N (4r)-4-[3-[(1r)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-MNOVXSKESA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-GHMZBOCLSA-N (4s)-4-[3-[(1r)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-GHMZBOCLSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-WDEREUQCSA-N (4s)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-WDEREUQCSA-N 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 1
- OMMRWLRXHDDLKE-UHFFFAOYSA-N 1-[1-(5-chloro-3-cyclopropyl-2-methoxy-4-methylphenyl)ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CC1 OMMRWLRXHDDLKE-UHFFFAOYSA-N 0.000 claims 1
- WYLJPAITMGWJRQ-UHFFFAOYSA-N 1-[1-[3-(1-butan-2-ylazetidin-3-yl)-5-chloro-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1N(C(C)CC)CC1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC WYLJPAITMGWJRQ-UHFFFAOYSA-N 0.000 claims 1
- WUNNBRIRNAKJLH-UHFFFAOYSA-N 1-[1-[4,5-dichloro-2-methoxy-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(C(C)C)C1 WUNNBRIRNAKJLH-UHFFFAOYSA-N 0.000 claims 1
- JUIUKAYNNVNLFM-UHFFFAOYSA-N 1-[1-[4,5-dichloro-2-methoxy-3-[1-(oxetan-3-yl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C(C1)CN1C1COC1 JUIUKAYNNVNLFM-UHFFFAOYSA-N 0.000 claims 1
- RMFYBQIIKKPTTD-UHFFFAOYSA-N 1-[1-[4,5-dichloro-3-(1-ethylazetidin-3-yl)-2-methoxyphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1N(CC)CC1C1=C(Cl)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC RMFYBQIIKKPTTD-UHFFFAOYSA-N 0.000 claims 1
- FSOPVIXIALYKMT-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-fluoro-3-(1-methylazetidin-3-yl)phenyl]ethyl]-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C)C1 FSOPVIXIALYKMT-UHFFFAOYSA-N 0.000 claims 1
- OQOHCCLTCJIZQH-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-fluoro-3-(1-methylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C)C1 OQOHCCLTCJIZQH-UHFFFAOYSA-N 0.000 claims 1
- YAJLBPCDJZEOJM-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-fluoro-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C(C)C)C1 YAJLBPCDJZEOJM-UHFFFAOYSA-N 0.000 claims 1
- DKWCACOYZCVWAR-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-fluoro-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C(C)C)C1 DKWCACOYZCVWAR-UHFFFAOYSA-N 0.000 claims 1
- FCICEBDJPUNKNB-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-fluoro-3-[1-(2,2,2-trifluoroethyl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CC(F)(F)F)C1 FCICEBDJPUNKNB-UHFFFAOYSA-N 0.000 claims 1
- RFLSSBHYORKXQB-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-methyl-3-(1-methylpyrazol-4-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C=1C=NN(C)C=1 RFLSSBHYORKXQB-UHFFFAOYSA-N 0.000 claims 1
- JZKHRHRYEVKZRK-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-methyl-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(C)C)C1 JZKHRHRYEVKZRK-UHFFFAOYSA-N 0.000 claims 1
- YKMZDDYLYFBBCE-UHFFFAOYSA-N 1-[1-[5-chloro-2-ethoxy-4-methyl-3-(5-methylsulfonylpyridin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(S(C)(=O)=O)=C1 YKMZDDYLYFBBCE-UHFFFAOYSA-N 0.000 claims 1
- IOWGPAQKAOOXNJ-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-3-[1-(2-methoxyethyl)azetidin-3-yl]-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1N(CCOC)CC1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC IOWGPAQKAOOXNJ-UHFFFAOYSA-N 0.000 claims 1
- BVISSWCHEUOQLQ-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-(1-methylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C)C1 BVISSWCHEUOQLQ-UHFFFAOYSA-N 0.000 claims 1
- QQLYWGQNVSLCFL-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-(1-methylpiperidin-4-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CCN(C)CC1 QQLYWGQNVSLCFL-UHFFFAOYSA-N 0.000 claims 1
- BWPVHVGKTKQLSR-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(C)=C1C1CN(C(C)C)C1 BWPVHVGKTKQLSR-UHFFFAOYSA-N 0.000 claims 1
- KVXTVARPRRDFIC-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(C)C)C1 KVXTVARPRRDFIC-UHFFFAOYSA-N 0.000 claims 1
- IZJVOUIFSFDESE-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-(5-methylsulfonylpyridin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(S(C)(=O)=O)=C1 IZJVOUIFSFDESE-UHFFFAOYSA-N 0.000 claims 1
- VZUKFCYWZYFFIL-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(=C1)C=NN1C1CCN(C)CC1 VZUKFCYWZYFFIL-UHFFFAOYSA-N 0.000 claims 1
- CELNSDNTUCEZMR-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-[1-(2,2,2-trifluoroethyl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(F)(F)F)C1 CELNSDNTUCEZMR-UHFFFAOYSA-N 0.000 claims 1
- WAVKYLNJUFLKTN-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-[1-(oxan-4-yl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C1CCOCC1 WAVKYLNJUFLKTN-UHFFFAOYSA-N 0.000 claims 1
- JVIVLWMFLLLIRQ-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-[1-(oxetan-3-yl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C1COC1 JVIVLWMFLLLIRQ-UHFFFAOYSA-N 0.000 claims 1
- LNEMXRLXBGKBPW-UHFFFAOYSA-N 1-[1-[5-chloro-2-methoxy-4-methyl-3-[1-(oxolan-3-yl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C1CCOC1 LNEMXRLXBGKBPW-UHFFFAOYSA-N 0.000 claims 1
- QGPOJKNXFVJKMW-UHFFFAOYSA-N 1-[1-[5-chloro-3-(cyclopropylmethyl)-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound CC1=C(Cl)C=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C(OC)=C1CC1CC1 QGPOJKNXFVJKMW-UHFFFAOYSA-N 0.000 claims 1
- BGAUCVBAAUHEDE-UHFFFAOYSA-N 1-[1-[5-chloro-3-[1-(1-fluoropropan-2-yl)azetidin-3-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(C)CF)C1 BGAUCVBAAUHEDE-UHFFFAOYSA-N 0.000 claims 1
- GZWKYXNHQQGREC-UHFFFAOYSA-N 1-[1-[5-chloro-3-[1-(2,2-difluoroethyl)azetidin-3-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(F)F)C1 GZWKYXNHQQGREC-UHFFFAOYSA-N 0.000 claims 1
- OUELJXRVIBGBSC-UHFFFAOYSA-N 1-[1-[5-chloro-3-[1-(cyclopropylmethyl)azetidin-3-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1CC1CC1 OUELJXRVIBGBSC-UHFFFAOYSA-N 0.000 claims 1
- YPLUJLSBEXFVAU-UHFFFAOYSA-N 1-[1-[5-chloro-3-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C=1C=NN(CCN(C)C)C=1 YPLUJLSBEXFVAU-UHFFFAOYSA-N 0.000 claims 1
- ZHKZHFHOPSQKTM-UHFFFAOYSA-N 1-[1-[5-chloro-3-[2-(dimethylamino)pyridin-4-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(N(C)C)=C1 ZHKZHFHOPSQKTM-UHFFFAOYSA-N 0.000 claims 1
- JNZBWXGNZSMJMQ-UHFFFAOYSA-N 1-[1-[5-chloro-3-[6-(dimethylamino)pyridin-3-yl]-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(N(C)C)N=C1 JNZBWXGNZSMJMQ-UHFFFAOYSA-N 0.000 claims 1
- VSAZWRHMIUNBII-UHFFFAOYSA-N 1-[1-[5-chloro-4-fluoro-2-methoxy-3-(1-methylazetidin-3-yl)phenyl]ethyl]-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C)C1 VSAZWRHMIUNBII-UHFFFAOYSA-N 0.000 claims 1
- QGARQSCJBPNHNL-UHFFFAOYSA-N 1-[1-[5-chloro-4-fluoro-2-methoxy-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(C(C)C)C1 QGARQSCJBPNHNL-UHFFFAOYSA-N 0.000 claims 1
- WFJBTQYBCMJYNG-UHFFFAOYSA-N 1-[1-[5-chloro-4-fluoro-2-methoxy-3-(1-propan-2-ylazetidin-3-yl)phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(C(C)C)C1 WFJBTQYBCMJYNG-UHFFFAOYSA-N 0.000 claims 1
- AXJSCTCJUHSYBE-UHFFFAOYSA-N 1-[1-[5-chloro-4-fluoro-2-methoxy-3-[1-(oxetan-3-yl)azetidin-3-yl]phenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C(C1)CN1C1COC1 AXJSCTCJUHSYBE-UHFFFAOYSA-N 0.000 claims 1
- MBAFAGVCOYZNOX-UHFFFAOYSA-N 1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]-2-methylpropan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CC(C)(C)O)C1 MBAFAGVCOYZNOX-UHFFFAOYSA-N 0.000 claims 1
- FRLYPMNWGJJLEF-UHFFFAOYSA-N 1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]-2-methylpropan-2-ol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(C)(C)O)C1 FRLYPMNWGJJLEF-UHFFFAOYSA-N 0.000 claims 1
- GENAFRGLARHVMD-UHFFFAOYSA-N 1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-2-hydroxy-2-methylpropan-1-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(=O)C(C)(C)O)C1 GENAFRGLARHVMD-UHFFFAOYSA-N 0.000 claims 1
- PTFWTPFDLLZEPS-UHFFFAOYSA-N 1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-2-methylpropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(C)(C)O)C1 PTFWTPFDLLZEPS-UHFFFAOYSA-N 0.000 claims 1
- GFOLYFQUUQLCIM-UHFFFAOYSA-N 1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CC1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC GFOLYFQUUQLCIM-UHFFFAOYSA-N 0.000 claims 1
- YEPQYHYCTPHTBV-UHFFFAOYSA-N 1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]-2-methylpropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(CC(C)(C)O)C1 YEPQYHYCTPHTBV-UHFFFAOYSA-N 0.000 claims 1
- PLVQCJNTGDAXRS-UHFFFAOYSA-N 1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]ethanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(C(C)=O)C1 PLVQCJNTGDAXRS-UHFFFAOYSA-N 0.000 claims 1
- OQMGPRGFANVWCT-UHFFFAOYSA-N 1-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-fluoro-6-methoxyphenyl]azetidin-1-yl]-2-methylpropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CC(C)(C)O)C1 OQMGPRGFANVWCT-UHFFFAOYSA-N 0.000 claims 1
- HEQBQJMVHVFQFC-UHFFFAOYSA-N 1-[4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]piperidin-1-yl]-2-methylpropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CCN(CC(C)(C)O)CC1 HEQBQJMVHVFQFC-UHFFFAOYSA-N 0.000 claims 1
- WPJDICFYMRHROM-UHFFFAOYSA-N 1-[4-[4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyrazol-1-yl]piperidin-1-yl]ethanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(=C1)C=NN1C1CCN(C(C)=O)CC1 WPJDICFYMRHROM-UHFFFAOYSA-N 0.000 claims 1
- MQKXQTKJRRACPT-UHFFFAOYSA-N 1-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidine-3-carbonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1N1CC(C#N)C1 MQKXQTKJRRACPT-UHFFFAOYSA-N 0.000 claims 1
- ROKNAOOYXYQMEU-UHFFFAOYSA-N 1-[5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridine-3-carbonyl]azetidine-3-carbonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C=1)=CN=CC=1C(=O)N1CC(C#N)C1 ROKNAOOYXYQMEU-UHFFFAOYSA-N 0.000 claims 1
- KZHQTNPGNQFKMC-UHFFFAOYSA-N 2-(1-acetylazetidin-3-yl)-4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)=O)C1 KZHQTNPGNQFKMC-UHFFFAOYSA-N 0.000 claims 1
- PWGIGBFGHYFIBK-UHFFFAOYSA-N 2-(1-acetylazetidin-3-yl)-4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)=O)C1 PWGIGBFGHYFIBK-UHFFFAOYSA-N 0.000 claims 1
- WPLLONBBBBTHIP-UHFFFAOYSA-N 2-[1-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]cyclobutyl]acetonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C1(CC#N)CCC1 WPLLONBBBBTHIP-UHFFFAOYSA-N 0.000 claims 1
- TUEGHGDQSFFJCR-UHFFFAOYSA-N 2-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]acetonitrile Chemical compound COC1=C(CC#N)C(C)=C(Cl)C=C1C(C)N1C2=NC=NC(N)=C2C(C)=N1 TUEGHGDQSFFJCR-UHFFFAOYSA-N 0.000 claims 1
- ZTTGEWWYMWJPHJ-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]acetamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CC(N)=O)C1 ZTTGEWWYMWJPHJ-UHFFFAOYSA-N 0.000 claims 1
- OOFVSYAIFFUZAM-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]ethanol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CCO)C1 OOFVSYAIFFUZAM-UHFFFAOYSA-N 0.000 claims 1
- UWELQOKGACQCNG-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]ethanol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CCO)C1 UWELQOKGACQCNG-UHFFFAOYSA-N 0.000 claims 1
- VJBZYNUINOYICB-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-3,3,3-trifluoropropan-1-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(CO)C(F)(F)F)C1 VJBZYNUINOYICB-UHFFFAOYSA-N 0.000 claims 1
- SYLDFZDXMGHAHP-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]acetamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(N)=O)C1 SYLDFZDXMGHAHP-UHFFFAOYSA-N 0.000 claims 1
- DVVNMGCJKBIXHN-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]acetonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC#N)C1 DVVNMGCJKBIXHN-UHFFFAOYSA-N 0.000 claims 1
- JBCBZHKCOKPHKX-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]ethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CCO)C1 JBCBZHKCOKPHKX-UHFFFAOYSA-N 0.000 claims 1
- DJNDEKXHLAWIML-UHFFFAOYSA-N 2-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]propanenitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(C(C)C#N)C1 DJNDEKXHLAWIML-UHFFFAOYSA-N 0.000 claims 1
- OMWMDQLAODHBCM-UHFFFAOYSA-N 2-[3-[3-[1-[4-amino-3-(1-methylpyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]acetonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CN(C)N=C3)=N2)C=C(Cl)C(C)=C1C1CN(CC#N)C1 OMWMDQLAODHBCM-UHFFFAOYSA-N 0.000 claims 1
- MWWOYWLTFYQTPP-UHFFFAOYSA-N 2-[3-[3-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]acetonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CNN=C3)=N2)C=C(Cl)C(C)=C1C1CN(CC#N)C1 MWWOYWLTFYQTPP-UHFFFAOYSA-N 0.000 claims 1
- QIUBAVSRQAJLHV-UHFFFAOYSA-N 2-[3-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]azetidin-1-yl]ethanol Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(CCO)C1 QIUBAVSRQAJLHV-UHFFFAOYSA-N 0.000 claims 1
- OCILFYDOEKWMEW-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]acetonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(Cl)=C1C1CN(CC#N)C1 OCILFYDOEKWMEW-UHFFFAOYSA-N 0.000 claims 1
- IRSHORZQIUSICQ-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2,3-dichloro-6-methoxyphenyl]azetidin-1-yl]ethanol Chemical compound NC1=C2C(=NC=N1)N(N=C2C)C(C)C=1C(=C(C(=C(C=1)Cl)Cl)C1CN(C1)CCO)OC IRSHORZQIUSICQ-UHFFFAOYSA-N 0.000 claims 1
- QCNVWRCCTQZPQV-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidin-1-yl]-2-methylpropanamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)(C)C(N)=O)C1 QCNVWRCCTQZPQV-UHFFFAOYSA-N 0.000 claims 1
- GSTJCAXUOLBAMZ-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidin-1-yl]-n,2-dimethylpropanamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)(C)C(=O)NC)C1 GSTJCAXUOLBAMZ-UHFFFAOYSA-N 0.000 claims 1
- NENSZFPDCTVZCA-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidin-1-yl]-n,n,2-trimethylpropanamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)(C)C(=O)N(C)C)C1 NENSZFPDCTVZCA-UHFFFAOYSA-N 0.000 claims 1
- MLARYDAXPYMQPL-UHFFFAOYSA-N 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-fluoro-6-methoxyphenyl]azetidin-1-yl]ethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CN(CCO)C1 MLARYDAXPYMQPL-UHFFFAOYSA-N 0.000 claims 1
- FXYYRCLDRBLGLE-UHFFFAOYSA-N 2-[3-[5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-chloro-2-fluoro-6-methoxyphenyl]azetidin-1-yl]ethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(F)=C1C1CN(CCO)C1 FXYYRCLDRBLGLE-UHFFFAOYSA-N 0.000 claims 1
- UXTGQWWQMSXIHY-UHFFFAOYSA-N 2-[[5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridin-2-yl]amino]ethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(NCCO)N=C1 UXTGQWWQMSXIHY-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- DWNHWODSDASXQL-UHFFFAOYSA-N 3-(1-acetylazetidin-3-yl)-5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-4-methoxy-2-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(C(C)=O)C1 DWNHWODSDASXQL-UHFFFAOYSA-N 0.000 claims 1
- ZXJQEONXJODXNF-UHFFFAOYSA-N 3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-(3,5-difluorophenyl)-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1C1=CC(F)=CC(F)=C1 ZXJQEONXJODXNF-UHFFFAOYSA-N 0.000 claims 1
- FCDNPSKPJCDICB-UHFFFAOYSA-N 3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylbenzonitrile Chemical compound C1=C(Cl)C(C)=C(C#N)C(OCC)=C1C(C)N1C2=NC=NC(N)=C2C(C)=N1 FCDNPSKPJCDICB-UHFFFAOYSA-N 0.000 claims 1
- QOMSHSGBNJTTBF-UHFFFAOYSA-N 3-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-N-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C3=CNN=C3)=N2)=C1OCC QOMSHSGBNJTTBF-UHFFFAOYSA-N 0.000 claims 1
- YBSVOGCAZYSWOK-UHFFFAOYSA-N 3-[1-[4-amino-3-(1h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C4NN=CC4=CC=3)=N2)=C1OCC YBSVOGCAZYSWOK-UHFFFAOYSA-N 0.000 claims 1
- GKAAKWJWBZKIGE-UHFFFAOYSA-N 3-[1-[4-amino-3-(1h-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C4C=CNC4=CC=3)=N2)=C1OCC GKAAKWJWBZKIGE-UHFFFAOYSA-N 0.000 claims 1
- WMARVFKDNUJMDW-UHFFFAOYSA-N 3-[1-[4-amino-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C4C=CNC4=NC=3)=N2)=C1OCC WMARVFKDNUJMDW-UHFFFAOYSA-N 0.000 claims 1
- IBBUVKWTSDSITE-UHFFFAOYSA-N 3-[1-[4-amino-3-(2-amino-1,3-benzothiazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C4SC(N)=NC4=CC=3)=N2)=C1OCC IBBUVKWTSDSITE-UHFFFAOYSA-N 0.000 claims 1
- GMVYOEGUJRBUSS-UHFFFAOYSA-N 3-[1-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C4N=C(N)OC4=CC=3)=N2)=C1OCC GMVYOEGUJRBUSS-UHFFFAOYSA-N 0.000 claims 1
- GRFVIMWLCZSKTB-UHFFFAOYSA-N 3-[1-[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-n-ethyl-6-methylbenzamide Chemical compound CCNC(=O)C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(F)C=C(O)C=3)=N2)=C1OCC GRFVIMWLCZSKTB-UHFFFAOYSA-N 0.000 claims 1
- CWCRGAQAZXYCCJ-UHFFFAOYSA-N 3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC)CC1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC CWCRGAQAZXYCCJ-UHFFFAOYSA-N 0.000 claims 1
- UIZKSFVGVUNDFB-UHFFFAOYSA-N 3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylpropanamide Chemical compound CNC(=O)CCC1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC UIZKSFVGVUNDFB-UHFFFAOYSA-N 0.000 claims 1
- GOLQSWXUIZQBOS-UHFFFAOYSA-N 3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]cyclobutan-1-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CC(O)C1 GOLQSWXUIZQBOS-UHFFFAOYSA-N 0.000 claims 1
- DGQJWGJTTFCTAE-UHFFFAOYSA-N 3-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylbenzamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=CC(C(=O)N(C)C)=C1 DGQJWGJTTFCTAE-UHFFFAOYSA-N 0.000 claims 1
- GWTTVTZZVDBTMB-UHFFFAOYSA-N 3-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylbenzenesulfonamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=CC(S(=O)(=O)N(C)C)=C1 GWTTVTZZVDBTMB-UHFFFAOYSA-N 0.000 claims 1
- ZTUGTNZSYGNOFE-UHFFFAOYSA-N 3-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-1,1,1-trifluoropropan-2-ol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(O)C(F)(F)F)C1 ZTUGTNZSYGNOFE-UHFFFAOYSA-N 0.000 claims 1
- VJDCSAJOSXRANY-UHFFFAOYSA-N 3-[3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-2-methylpropanenitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CN(CC(C)C#N)C1 VJDCSAJOSXRANY-UHFFFAOYSA-N 0.000 claims 1
- FSENVPSVXHTCND-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylazetidine-1-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)N(C)C)C1 FSENVPSVXHTCND-UHFFFAOYSA-N 0.000 claims 1
- HHFHPZCNCGRYSA-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n-ethylazetidine-1-carboxamide Chemical compound C1N(C(=O)NCC)CC1C1=C(OCC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N HHFHPZCNCGRYSA-UHFFFAOYSA-N 0.000 claims 1
- YQNXBWCPBPPQNG-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n-methylazetidine-1-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)NC)C1 YQNXBWCPBPPQNG-UHFFFAOYSA-N 0.000 claims 1
- HIAUIXOCSLFPKP-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n-tert-butylazetidine-1-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)NC(C)(C)C)C1 HIAUIXOCSLFPKP-UHFFFAOYSA-N 0.000 claims 1
- FRRSLHDFEVZTPH-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-n,n-dimethylazetidine-1-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)N(C)C)C1 FRRSLHDFEVZTPH-UHFFFAOYSA-N 0.000 claims 1
- XIWFPOJEHQXANW-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-n-ethylazetidine-1-carboxamide Chemical compound C1N(C(=O)NCC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N XIWFPOJEHQXANW-UHFFFAOYSA-N 0.000 claims 1
- VUHLYNMOPZYTEK-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-n-methylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N VUHLYNMOPZYTEK-UHFFFAOYSA-N 0.000 claims 1
- NGSFHDXBDLNNPM-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-n-tert-butylazetidine-1-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)NC(C)(C)C)C1 NGSFHDXBDLNNPM-UHFFFAOYSA-N 0.000 claims 1
- MJVXTRGIJKQFHG-UHFFFAOYSA-N 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]azetidine-1-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(N)=O)C1 MJVXTRGIJKQFHG-UHFFFAOYSA-N 0.000 claims 1
- AIOUQYUFHADEHR-UHFFFAOYSA-N 3-methylpyridine-2-carboxamide Chemical compound CC1=CC=CN=C1C(N)=O AIOUQYUFHADEHR-UHFFFAOYSA-N 0.000 claims 1
- XGARCYYYFPWMKC-IAPIXIRKSA-N 4-[(1R)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-(2-oxo-1,3-oxazolidin-5-yl)benzonitrile Chemical compound CCOc1c(cc(Cl)c(C#N)c1C1CNC(=O)O1)[C@@H](C)n1nc(C)c2c(N)ncnc12 XGARCYYYFPWMKC-IAPIXIRKSA-N 0.000 claims 1
- ITEITQVKTJSFFX-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-(azetidin-3-yl)-6-chloro-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CNC1 ITEITQVKTJSFFX-UHFFFAOYSA-N 0.000 claims 1
- PJXOQIHPWFBWNB-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-(azetidin-3-yl)-6-chloro-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CNC1 PJXOQIHPWFBWNB-UHFFFAOYSA-N 0.000 claims 1
- VMEDCGGYYKALPX-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]-3-methoxy-6-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1CN(CC(C)(C)O)C1 VMEDCGGYYKALPX-UHFFFAOYSA-N 0.000 claims 1
- PNRYWUJRDIJNKG-CFMCSPIPSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]-3-methoxy-6-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1CN(C[C@H](C)O)C1 PNRYWUJRDIJNKG-CFMCSPIPSA-N 0.000 claims 1
- NDKDVJVSBLWXFS-QBRMTTIGSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-chloro-1,4,5,6-tetradeuterio-6-[1-(2-hydroxyethyl)azetidin-3-yl]-5-methoxycyclohex-2-ene-1-carbonitrile Chemical compound NC1=C2C(=NC=N1)N(N=C2C)C(C)C1(C(C(C(C#N)(C(=C1)Cl)[2H])(C1CN(C1)CCO)[2H])(OC)[2H])[2H] NDKDVJVSBLWXFS-QBRMTTIGSA-N 0.000 claims 1
- GRMHNISBQAWILC-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-ethoxy-2-[1-(2-hydroxyethyl)azetidin-3-yl]-6-methylbenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1CN(CCO)C1 GRMHNISBQAWILC-UHFFFAOYSA-N 0.000 claims 1
- XBKSABZOJVXHRZ-LBAUFKAWSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-ethoxy-2-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]-6-methylbenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1CN(C[C@H](C)O)C1 XBKSABZOJVXHRZ-LBAUFKAWSA-N 0.000 claims 1
- BIWLMIRVKBSFQI-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-ethoxy-6-methyl-2-(1-methylpyrazol-4-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C=1C=NN(C)C=1 BIWLMIRVKBSFQI-UHFFFAOYSA-N 0.000 claims 1
- IECAGZBMWJQJMS-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-ethoxy-6-methyl-2-(1-propan-2-ylazetidin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1CN(C(C)C)C1 IECAGZBMWJQJMS-UHFFFAOYSA-N 0.000 claims 1
- ZZVHFNRZGOZYJV-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-ethoxy-6-methyl-2-(5-methylsulfonylpyridin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CN=CC(S(C)(=O)=O)=C1 ZZVHFNRZGOZYJV-UHFFFAOYSA-N 0.000 claims 1
- CWLGWANCAOKWDL-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-methoxy-6-methyl-2-(5-methylsulfonylpyridin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CN=CC(S(C)(=O)=O)=C1 CWLGWANCAOKWDL-UHFFFAOYSA-N 0.000 claims 1
- QUCHHODLYZYMGC-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-(1-cyclobutylazetidin-3-yl)-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCC1 QUCHHODLYZYMGC-UHFFFAOYSA-N 0.000 claims 1
- OUIMJCJSIBATHP-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-(1-cyclobutylazetidin-3-yl)-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCC1 OUIMJCJSIBATHP-UHFFFAOYSA-N 0.000 claims 1
- IDJJUXQCGFEEMS-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-(1-cyclopropylsulfonylazetidin-3-yl)-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1S(=O)(=O)C1CC1 IDJJUXQCGFEEMS-UHFFFAOYSA-N 0.000 claims 1
- PBCQWOSTPCTHRD-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-(1-ethylazetidin-3-yl)-3-methoxybenzonitrile Chemical compound C1N(CC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N PBCQWOSTPCTHRD-UHFFFAOYSA-N 0.000 claims 1
- SAUFCGVJPPRKTQ-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-(1-ethylsulfonylazetidin-3-yl)-3-methoxybenzonitrile Chemical compound C1N(S(=O)(=O)CC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N SAUFCGVJPPRKTQ-UHFFFAOYSA-N 0.000 claims 1
- SZGPIMCGZNYFKO-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(1,3-dimethoxypropan-2-yl)azetidin-3-yl]-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(COC)COC)C1 SZGPIMCGZNYFKO-UHFFFAOYSA-N 0.000 claims 1
- GRBZLNYOYNNPLR-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)C(C)(C)C)C1 GRBZLNYOYNNPLR-UHFFFAOYSA-N 0.000 claims 1
- ZYYBPQOUQVKJNI-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(2-hydroxyethyl)azetidin-3-yl]-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CCO)C1 ZYYBPQOUQVKJNI-UHFFFAOYSA-N 0.000 claims 1
- OLGYOFLRVGHHNU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(cyanomethyl)azetidin-3-yl]-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CC#N)C1 OLGYOFLRVGHHNU-UHFFFAOYSA-N 0.000 claims 1
- UDNTZJAIECMPIP-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(cyclopropanecarbonyl)azetidin-3-yl]-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C(=O)C1CC1 UDNTZJAIECMPIP-UHFFFAOYSA-N 0.000 claims 1
- VVGLINSIWVCUJU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(cyclopropanecarbonyl)azetidin-3-yl]-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C(=O)C1CC1 VVGLINSIWVCUJU-UHFFFAOYSA-N 0.000 claims 1
- FGFDUYXZAAZWEP-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(cyclopropylmethyl)azetidin-3-yl]-3-ethoxybenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CC1 FGFDUYXZAAZWEP-UHFFFAOYSA-N 0.000 claims 1
- DHMAUKKOJFKQKU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-(cyclopropylmethyl)azetidin-3-yl]-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CC1 DHMAUKKOJFKQKU-UHFFFAOYSA-N 0.000 claims 1
- KLKCQNBHXXLCHY-JTDNENJMSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-[(2r)-2-hydroxypropyl]azetidin-3-yl]-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C[C@@H](C)O)C1 KLKCQNBHXXLCHY-JTDNENJMSA-N 0.000 claims 1
- KLKCQNBHXXLCHY-AMGKYWFPSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-2-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]-3-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C[C@H](C)O)C1 KLKCQNBHXXLCHY-AMGKYWFPSA-N 0.000 claims 1
- SWUXBCAWGABMGD-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-(1-ethylsulfonylazetidin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(S(=O)(=O)CC)C1 SWUXBCAWGABMGD-UHFFFAOYSA-N 0.000 claims 1
- MCRIWRBTFCRQSY-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-(1-methylsulfonylazetidin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(S(C)(=O)=O)C1 MCRIWRBTFCRQSY-UHFFFAOYSA-N 0.000 claims 1
- GNKXJUPRROBESG-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-(1-propan-2-ylsulfonylazetidin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(S(=O)(=O)C(C)C)C1 GNKXJUPRROBESG-UHFFFAOYSA-N 0.000 claims 1
- GZMKBXXTFROUMP-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-(5-methylsulfonylpyridin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CN=CC(S(C)(=O)=O)=C1 GZMKBXXTFROUMP-UHFFFAOYSA-N 0.000 claims 1
- AKAKVHZITLXTAC-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(1-hydroxy-2-methylpropan-2-yl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)(C)CO)C1 AKAKVHZITLXTAC-UHFFFAOYSA-N 0.000 claims 1
- ZKWCSUHNNUZXJE-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(1-hydroxypropan-2-yl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)CO)C1 ZKWCSUHNNUZXJE-UHFFFAOYSA-N 0.000 claims 1
- LHOWBTROKICTRB-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(2,2,2-trifluoroethyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CC(F)(F)F)C1 LHOWBTROKICTRB-UHFFFAOYSA-N 0.000 claims 1
- YWZBSHAJAYTKLC-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)C(C)(C)O)C1 YWZBSHAJAYTKLC-UHFFFAOYSA-N 0.000 claims 1
- KVACQGVXNIMCIE-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CC(C)(C)O)C1 KVACQGVXNIMCIE-UHFFFAOYSA-N 0.000 claims 1
- BDDZANHGMPZWSJ-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(3,3,3-trifluoropropyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CCC(F)(F)F)C1 BDDZANHGMPZWSJ-UHFFFAOYSA-N 0.000 claims 1
- JLEBEUCBHCDAAA-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(oxan-4-yl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCOCC1 JLEBEUCBHCDAAA-UHFFFAOYSA-N 0.000 claims 1
- DXGKJGAEYCAZJU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(oxan-4-ylmethyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CCOCC1 DXGKJGAEYCAZJU-UHFFFAOYSA-N 0.000 claims 1
- BWWDEQZFIPGWCG-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(oxolan-3-yl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCOC1 BWWDEQZFIPGWCG-UHFFFAOYSA-N 0.000 claims 1
- STJZSLXQQIEDLE-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-(oxolan-3-ylmethyl)azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CCOC1 STJZSLXQQIEDLE-UHFFFAOYSA-N 0.000 claims 1
- MCIRQIFXNINZHL-PUODRLBUSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-[(2r)-2-hydroxypropyl]azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C[C@@H](C)O)C1 MCIRQIFXNINZHL-PUODRLBUSA-N 0.000 claims 1
- MCIRQIFXNINZHL-NBFOIZRFSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C[C@H](C)O)C1 MCIRQIFXNINZHL-NBFOIZRFSA-N 0.000 claims 1
- RTIFIPCKKIJSKD-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[3-(methoxymethyl)azetidin-1-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1N1CC(COC)C1 RTIFIPCKKIJSKD-UHFFFAOYSA-N 0.000 claims 1
- HLNPCHVPPSSFJF-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[5-(1,3-oxazol-2-yl)pyridin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C=1)=CN=CC=1C1=NC=CO1 HLNPCHVPPSSFJF-UHFFFAOYSA-N 0.000 claims 1
- OENYPRFDLZKNFC-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CC=C(C(C)(C)O)N=C1 OENYPRFDLZKNFC-UHFFFAOYSA-N 0.000 claims 1
- ZVKBFCGBELOHKY-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-pyrimidin-5-ylbenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CN=CN=C1 ZVKBFCGBELOHKY-UHFFFAOYSA-N 0.000 claims 1
- GZPOZNLKRAMBLT-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-ethoxy-2-pyrrolidin-1-ylbenzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1N1CCCC1 GZPOZNLKRAMBLT-UHFFFAOYSA-N 0.000 claims 1
- OWQMJTFVVTZJKY-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-(1-methylsulfonylazetidin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(S(C)(=O)=O)C1 OWQMJTFVVTZJKY-UHFFFAOYSA-N 0.000 claims 1
- UGADQIDSYFDZGQ-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-(1-propan-2-ylazetidin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)C)C1 UGADQIDSYFDZGQ-UHFFFAOYSA-N 0.000 claims 1
- XZVJVDMFFGQDRG-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-(1-propan-2-ylsulfonylazetidin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(S(=O)(=O)C(C)C)C1 XZVJVDMFFGQDRG-UHFFFAOYSA-N 0.000 claims 1
- RHNYPRNOZDCEDY-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-(5-methylsulfonylpyridin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CN=CC(S(C)(=O)=O)=C1 RHNYPRNOZDCEDY-UHFFFAOYSA-N 0.000 claims 1
- ZGHBNTTVFVZUES-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(2-methylpropanoyl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)C(C)C)C1 ZGHBNTTVFVZUES-UHFFFAOYSA-N 0.000 claims 1
- YQOCDMFKKLHYAU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(2-methylpropyl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(CC(C)C)C1 YQOCDMFKKLHYAU-UHFFFAOYSA-N 0.000 claims 1
- OICQQMDXRMYLPW-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(oxan-4-yl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCOCC1 OICQQMDXRMYLPW-UHFFFAOYSA-N 0.000 claims 1
- SIKWOSDZUGQNOU-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(oxan-4-ylmethyl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CCOCC1 SIKWOSDZUGQNOU-UHFFFAOYSA-N 0.000 claims 1
- CWPWVVHEOHBUSV-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(oxetan-3-yl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1COC1 CWPWVVHEOHBUSV-UHFFFAOYSA-N 0.000 claims 1
- RYGJKWNOZQFFRZ-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(oxolan-3-yl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1C1CCOC1 RYGJKWNOZQFFRZ-UHFFFAOYSA-N 0.000 claims 1
- YBYXGBFFGVXBNK-UHFFFAOYSA-N 4-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-chloro-3-methoxy-2-[1-(oxolan-3-ylmethyl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C(C1)CN1CC1CCOC1 YBYXGBFFGVXBNK-UHFFFAOYSA-N 0.000 claims 1
- LXCBMDGJBNPUHR-MLCCFXAWSA-N 4-[1-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-6-chloro-3-ethoxy-2-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=C2)C=C(Cl)C(C#N)=C1C1CN(C[C@H](C)O)C1 LXCBMDGJBNPUHR-MLCCFXAWSA-N 0.000 claims 1
- MPNWWLXSJKXPKN-UHFFFAOYSA-N 4-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-6-chloro-3-ethoxy-2-(5-methylsulfonylpyridin-3-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C#N)=C1C1=CN=CC(S(C)(=O)=O)=C1 MPNWWLXSJKXPKN-UHFFFAOYSA-N 0.000 claims 1
- UCYDWQYLQRHHCX-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]-1,3-oxazolidin-2-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1COC(=O)N1 UCYDWQYLQRHHCX-UHFFFAOYSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CNC(=O)C1 ZQPDJCIXJHUERQ-UHFFFAOYSA-N 0.000 claims 1
- KLTDLHDMXSIRPS-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)C)=C1 KLTDLHDMXSIRPS-UHFFFAOYSA-N 0.000 claims 1
- FIAIVNIHVRXJSS-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n-(2-hydroxyethyl)-n-methylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)CCO)=C1 FIAIVNIHVRXJSS-UHFFFAOYSA-N 0.000 claims 1
- DCYPFCXQPSHQAV-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-2-fluoro-n,n-dimethylbenzamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)C(F)=C1 DCYPFCXQPSHQAV-UHFFFAOYSA-N 0.000 claims 1
- GKLBWXFAKAOGRL-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)C)=C1 GKLBWXFAKAOGRL-UHFFFAOYSA-N 0.000 claims 1
- SMTNSBXQKKGWLV-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)pyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)NCCO)=C1 SMTNSBXQKKGWLV-UHFFFAOYSA-N 0.000 claims 1
- SKAPLEFCLYIUAU-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(C=2C(=C(C(C)N3C4=NC=NC(N)=C4C(C)=N3)C=C(Cl)C=2C)OC)=C1 SKAPLEFCLYIUAU-UHFFFAOYSA-N 0.000 claims 1
- CGOOTFVIDYUBGF-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-cyano-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)-n-methylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C#N)C(C)=C1C1=CC=NC(C(=O)N(C)CCO)=C1 CGOOTFVIDYUBGF-UHFFFAOYSA-N 0.000 claims 1
- KPNNLKLNEVRVPW-UHFFFAOYSA-N 4-[3-[1-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)C)=C1 KPNNLKLNEVRVPW-UHFFFAOYSA-N 0.000 claims 1
- GFUWVUDUTZFZLS-UHFFFAOYSA-N 4-[3-[1-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)pyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)NCCO)=C1 GFUWVUDUTZFZLS-UHFFFAOYSA-N 0.000 claims 1
- WKZWNOVBZGKRGR-UHFFFAOYSA-N 4-[3-[1-[(6-amino-5-ethanimidoylpyrimidin-4-yl)amino]ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)NC=2C(=C(N)N=CN=2)C(C)=N)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)C)=C1 WKZWNOVBZGKRGR-UHFFFAOYSA-N 0.000 claims 1
- DWHGOGVUELEDRG-UHFFFAOYSA-N 4-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-cyano-6-ethoxy-3-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CC=NC(C(=O)N(C)C)=C1 DWHGOGVUELEDRG-UHFFFAOYSA-N 0.000 claims 1
- BJDVQZKDMAKKPM-UHFFFAOYSA-N 4-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CC=NC(C(=O)N(C)C)=C1 BJDVQZKDMAKKPM-UHFFFAOYSA-N 0.000 claims 1
- ZIMNJKKNCVHWOV-UHFFFAOYSA-N 4-amino-8-[1-(5-chloro-2-methoxy-4-methyl-3-pyridin-3-ylphenyl)ethyl]pyrido[2,3-d]pyrimidin-5-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=CN=C1 ZIMNJKKNCVHWOV-UHFFFAOYSA-N 0.000 claims 1
- UGMJKNBAEHXEAV-UHFFFAOYSA-N 4-amino-8-[1-(5-chloro-2-methoxy-4-methyl-3-pyrimidin-5-ylphenyl)ethyl]pyrido[2,3-d]pyrimidin-5-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CN=CN=C1 UGMJKNBAEHXEAV-UHFFFAOYSA-N 0.000 claims 1
- TVKCMRJHVAKGBR-UHFFFAOYSA-N 4-amino-8-[1-[5-chloro-2-methoxy-4-methyl-3-(5-methylsulfonylpyridin-3-yl)phenyl]ethyl]pyrido[2,3-d]pyrimidin-5-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CN=CC(S(C)(=O)=O)=C1 TVKCMRJHVAKGBR-UHFFFAOYSA-N 0.000 claims 1
- NLHXYFCSZPHVIO-UHFFFAOYSA-N 5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-ethoxy-2-methyl-3-(1-methylpyrazol-4-yl)benzonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C#N)C(C)=C1C=1C=NN(C)C=1 NLHXYFCSZPHVIO-UHFFFAOYSA-N 0.000 claims 1
- PFWHUFUHASEOFP-UHFFFAOYSA-N 5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-4-methoxy-2-methyl-3-(1-methylpyrazol-4-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C#N)C(C)=C1C=1C=NN(C)C=1 PFWHUFUHASEOFP-UHFFFAOYSA-N 0.000 claims 1
- WTISZRVMTGAQTB-UHFFFAOYSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-2-fluoro-3-[1-(2-hydroxyethyl)azetidin-3-yl]-4-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(F)=C1C1CN(CCO)C1 WTISZRVMTGAQTB-UHFFFAOYSA-N 0.000 claims 1
- LYGFCLHDXSUKSI-VUWPPUDQSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-2-fluoro-3-[1-[(2s)-2-hydroxypropyl]azetidin-3-yl]-4-methoxybenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(F)=C1C1CN(C[C@H](C)O)C1 LYGFCLHDXSUKSI-VUWPPUDQSA-N 0.000 claims 1
- YKLIUZKQUOCJPP-UHFFFAOYSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-[1-(2,2-difluoroethyl)azetidin-3-yl]-4-methoxy-2-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(CC(F)F)C1 YKLIUZKQUOCJPP-UHFFFAOYSA-N 0.000 claims 1
- OKLLIBZLGKJVBJ-UHFFFAOYSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-[1-(2-hydroxyethyl)azetidin-3-yl]-4-methoxy-2-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(CCO)C1 OKLLIBZLGKJVBJ-UHFFFAOYSA-N 0.000 claims 1
- SALBXLRGOLXPQY-JTDNENJMSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-[1-[(2r)-2-hydroxypropyl]azetidin-3-yl]-4-methoxy-2-methylbenzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(C[C@@H](C)O)C1 SALBXLRGOLXPQY-JTDNENJMSA-N 0.000 claims 1
- IDVAKCBQSLPPNH-UHFFFAOYSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-4-methoxy-2-methyl-3-(1-propan-2-ylazetidin-3-yl)benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(C(C)C)C1 IDVAKCBQSLPPNH-UHFFFAOYSA-N 0.000 claims 1
- GYWVNFICSRNCMU-UHFFFAOYSA-N 5-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-4-methoxy-2-methyl-3-[1-(2,2,2-trifluoroethyl)azetidin-3-yl]benzonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(C#N)C(C)=C1C1CN(CC(F)(F)F)C1 GYWVNFICSRNCMU-UHFFFAOYSA-N 0.000 claims 1
- JAOSUCRDSSWHBL-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-cyanopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C#N)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 JAOSUCRDSSWHBL-UHFFFAOYSA-N 0.000 claims 1
- RRSCRMHZMWUSFN-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-cyclopropylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3CC3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RRSCRMHZMWUSFN-UHFFFAOYSA-N 0.000 claims 1
- LWRCOZZUEDSSRB-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-ethylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LWRCOZZUEDSSRB-UHFFFAOYSA-N 0.000 claims 1
- MICRYOZLKDGIIJ-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(I)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MICRYOZLKDGIIJ-UHFFFAOYSA-N 0.000 claims 1
- RYYHOGBWUDOVBW-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RYYHOGBWUDOVBW-UHFFFAOYSA-N 0.000 claims 1
- AAAFOWLNHPEWFZ-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 AAAFOWLNHPEWFZ-UHFFFAOYSA-N 0.000 claims 1
- KUXSPGMRBZLSSK-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-3-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(C(=O)N(C)C)=C1 KUXSPGMRBZLSSK-UHFFFAOYSA-N 0.000 claims 1
- SPDKDKKGRGWOLC-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)NC)N=C1 SPDKDKKGRGWOLC-UHFFFAOYSA-N 0.000 claims 1
- NIZYKSCTQPOPRY-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-1,3-oxazolidin-2-one Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1CNC(=O)O1 NIZYKSCTQPOPRY-UHFFFAOYSA-N 0.000 claims 1
- KTVVAZSEWBIVSN-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 KTVVAZSEWBIVSN-UHFFFAOYSA-N 0.000 claims 1
- KATAAFRJKJMWFE-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-3-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(C(=O)N(C)C)=C1 KATAAFRJKJMWFE-UHFFFAOYSA-N 0.000 claims 1
- VTLYUEQNHLTQGU-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)-n-methylpyridine-3-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(C(=O)N(C)CCO)=C1 VTLYUEQNHLTQGU-UHFFFAOYSA-N 0.000 claims 1
- DUFBWILDUSBWOB-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)pyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)NCCO)N=C1 DUFBWILDUSBWOB-UHFFFAOYSA-N 0.000 claims 1
- ZNJMXQJKVYQJOK-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-cyclopropyl-n-methylpyridine-3-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C=1)=CN=CC=1C(=O)N(C)C1CC1 ZNJMXQJKVYQJOK-UHFFFAOYSA-N 0.000 claims 1
- PXFOWBGPZKANFA-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridine-3-carbonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CN=CC(C#N)=C1 PXFOWBGPZKANFA-UHFFFAOYSA-N 0.000 claims 1
- MRVLFHBXSHLHOL-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[4,3-c]pyridin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=CC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MRVLFHBXSHLHOL-UHFFFAOYSA-N 0.000 claims 1
- POXLGQURDCNRHS-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 POXLGQURDCNRHS-UHFFFAOYSA-N 0.000 claims 1
- YXXAZOUQFXBZTQ-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-pyridin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=CN=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 YXXAZOUQFXBZTQ-UHFFFAOYSA-N 0.000 claims 1
- GDSSXJRACKTBFD-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 GDSSXJRACKTBFD-UHFFFAOYSA-N 0.000 claims 1
- MKJFFPOJZAUGHO-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MKJFFPOJZAUGHO-UHFFFAOYSA-N 0.000 claims 1
- MYTVYESWXXZGCZ-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MYTVYESWXXZGCZ-UHFFFAOYSA-N 0.000 claims 1
- KBNSWEWQWKDWCH-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)=C1OC KBNSWEWQWKDWCH-UHFFFAOYSA-N 0.000 claims 1
- WSQLDPPVBLQZDE-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridine-3-carbonitrile Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CN=CC(C#N)=C1 WSQLDPPVBLQZDE-UHFFFAOYSA-N 0.000 claims 1
- ZWRFYVXHTLKEGN-UHFFFAOYSA-N 5-[3-[1-(4-amino-6-methyl-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C(C)=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 ZWRFYVXHTLKEGN-UHFFFAOYSA-N 0.000 claims 1
- RCULREUPLKRTQM-UHFFFAOYSA-N 5-[3-[1-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RCULREUPLKRTQM-UHFFFAOYSA-N 0.000 claims 1
- ZINVRKJXQWTMEP-UHFFFAOYSA-N 5-[3-[1-[(6-amino-5-ethanimidoylpyrimidin-4-yl)amino]ethyl]-5-chloro-2-(cyclopropylmethoxy)-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound C=1C(Cl)=C(C)C(C=2C=NC(=CC=2)C(=O)N(C)C)=C(OCC2CC2)C=1C(C)NC1=NC=NC(N)=C1C(C)=N ZINVRKJXQWTMEP-UHFFFAOYSA-N 0.000 claims 1
- NCKZBAHNOUNLOC-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1-methylpyrazol-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=NN(C)C=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 NCKZBAHNOUNLOC-UHFFFAOYSA-N 0.000 claims 1
- YUPRTAQNMSAZLS-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1-methylpyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CN(C)N=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 YUPRTAQNMSAZLS-UHFFFAOYSA-N 0.000 claims 1
- SLEODHBJUISKGK-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-N,N-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CNN=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 SLEODHBJUISKGK-UHFFFAOYSA-N 0.000 claims 1
- LQXVADVQSDQOEW-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1h-pyrazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=NNC=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LQXVADVQSDQOEW-UHFFFAOYSA-N 0.000 claims 1
- RPANFZBTBQXCEP-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(2-aminopyrimidin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC(N)=NC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RPANFZBTBQXCEP-UHFFFAOYSA-N 0.000 claims 1
- COEMEMLQEMXAPG-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(F)C=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 COEMEMLQEMXAPG-UHFFFAOYSA-N 0.000 claims 1
- FTBLQBUNWWAOJJ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=CC(F)=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 FTBLQBUNWWAOJJ-UHFFFAOYSA-N 0.000 claims 1
- DUXSSDXCLZIENR-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(5-cyanopyridin-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(C=NC=3)C#N)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 DUXSSDXCLZIENR-UHFFFAOYSA-N 0.000 claims 1
- VCQJHEDDPMLDPF-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(cyanomethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CC#N)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 VCQJHEDDPMLDPF-UHFFFAOYSA-N 0.000 claims 1
- PFCWFOYSXIUQJD-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 PFCWFOYSXIUQJD-UHFFFAOYSA-N 0.000 claims 1
- XVIFKEIMNFEGHE-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(fluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CF)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 XVIFKEIMNFEGHE-UHFFFAOYSA-N 0.000 claims 1
- OIQDMTOTTQKSIQ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(hydroxymethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CO)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 OIQDMTOTTQKSIQ-UHFFFAOYSA-N 0.000 claims 1
- RJLOXSYBHFJOBP-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(methylaminomethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CNC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RJLOXSYBHFJOBP-UHFFFAOYSA-N 0.000 claims 1
- UCAXJYWFVYLBCZ-LDCVWXEPSA-N 5-[3-[1-[4-amino-3-[(3r)-3-hydroxybut-1-ynyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C#C[C@@H](C)O)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 UCAXJYWFVYLBCZ-LDCVWXEPSA-N 0.000 claims 1
- UCAXJYWFVYLBCZ-MYJWUSKBSA-N 5-[3-[1-[4-amino-3-[(3s)-3-hydroxybut-1-ynyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C#C[C@H](C)O)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 UCAXJYWFVYLBCZ-MYJWUSKBSA-N 0.000 claims 1
- IDJOZOUOJMRPMD-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[(dimethylamino)methyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CN(C)C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 IDJOZOUOJMRPMD-UHFFFAOYSA-N 0.000 claims 1
- LODIZXIHZIZZJF-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[1-(2-hydroxyethyl)pyrazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CN(CCO)N=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LODIZXIHZIZZJF-UHFFFAOYSA-N 0.000 claims 1
- MJPPETLGDRBERR-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[5-(dimethylcarbamoyl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(C=NC=3)C(=O)N(C)C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MJPPETLGDRBERR-UHFFFAOYSA-N 0.000 claims 1
- DBQHZDZAOVUZFR-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[6-(dimethylcarbamoyl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC(=CC=3)C(=O)N(C)C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 DBQHZDZAOVUZFR-UHFFFAOYSA-N 0.000 claims 1
- ONVRGXQBLJXQAQ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[6-(methylcarbamoyl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC(=CC=3)C(=O)NC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 ONVRGXQBLJXQAQ-UHFFFAOYSA-N 0.000 claims 1
- STPOUNVLXXQXDX-UHFFFAOYSA-N 5-[3-[1-[4-amino-5-oxo-6-(1h-pyrazol-4-yl)pyrido[2,3-d]pyrimidin-8-yl]ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C(C3=CNN=C3)=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 STPOUNVLXXQXDX-UHFFFAOYSA-N 0.000 claims 1
- QMUKEAJHEZKJBD-UHFFFAOYSA-N 5-[3-[1-[[6-amino-5-(2,2-difluoroethanimidoyl)pyrimidin-4-yl]amino]ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)NC=2C(=C(N)N=CN=2)C(=N)C(F)F)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 QMUKEAJHEZKJBD-UHFFFAOYSA-N 0.000 claims 1
- ULQGXBVWPAKWKK-CYBMUJFWSA-N 5-[5-[(1R)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-N,N-dimethylpyridine-2-carboxamide Chemical compound COc1c(cc(Cl)c(C#N)c1-c1ccc(nc1)C(=O)N(C)C)[C@@H](C)n1nc(C)c2c(N)ncnc12 ULQGXBVWPAKWKK-CYBMUJFWSA-N 0.000 claims 1
- HJSUGXVDZRGDIL-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-cyano-6-ethoxy-3-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 HJSUGXVDZRGDIL-UHFFFAOYSA-N 0.000 claims 1
- HTZQCUXDUVHSIR-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-cyano-6-methoxy-3-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 HTZQCUXDUVHSIR-UHFFFAOYSA-N 0.000 claims 1
- WKGUYEULKUKCFJ-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 WKGUYEULKUKCFJ-UHFFFAOYSA-N 0.000 claims 1
- PXLODIDHFLAFLE-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-3-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CN=CC(C(=O)N(C)C)=C1 PXLODIDHFLAFLE-UHFFFAOYSA-N 0.000 claims 1
- FJCUDNUJUQXPPS-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n-methylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CC=C(C(=O)NC)N=C1 FJCUDNUJUQXPPS-UHFFFAOYSA-N 0.000 claims 1
- TXVHMNIEEBOWNB-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]pyridine-3-carbonitrile Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CN=CC(C#N)=C1 TXVHMNIEEBOWNB-UHFFFAOYSA-N 0.000 claims 1
- VHCJXZTZACMRTL-UHFFFAOYSA-N 5-[5-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 VHCJXZTZACMRTL-UHFFFAOYSA-N 0.000 claims 1
- WWWLCQHFGIAHBY-UHFFFAOYSA-N 6-[3-[1-[(6-amino-5-ethanimidoylpyrimidin-4-yl)amino]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-3-carboxamide Chemical compound CCOC1=C(C(C)NC=2C(=C(N)N=CN=2)C(C)=N)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)C=N1 WWWLCQHFGIAHBY-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- WSRDLWSIRIAWPX-UHFFFAOYSA-N CNC(=O)c1cc(cnc1CCN)-c1c(C)c(Cl)cc(C(C)n2nc(C)c3c(N)ncnc23)c1OC Chemical compound CNC(=O)c1cc(cnc1CCN)-c1c(C)c(Cl)cc(C(C)n2nc(C)c3c(N)ncnc23)c1OC WSRDLWSIRIAWPX-UHFFFAOYSA-N 0.000 claims 1
- 101150078024 CRY2 gene Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- WTSBHJMSFQJENA-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]azetidin-1-yl]-(1-methylpyrazol-4-yl)methanone Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C=1C=NN(C)C=1 WTSBHJMSFQJENA-UHFFFAOYSA-N 0.000 claims 1
- ADIDIOGKAWIIFU-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-(1-hydroxycyclopropyl)methanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C1(O)CC1 ADIDIOGKAWIIFU-UHFFFAOYSA-N 0.000 claims 1
- MIJQPAFFDSJUCM-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-(1-methylpyrazol-4-yl)methanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C=1C=NN(C)C=1 MIJQPAFFDSJUCM-UHFFFAOYSA-N 0.000 claims 1
- FBHZGJSGJXHTFB-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-(1h-pyrazol-4-yl)methanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C=1C=NNC=1 FBHZGJSGJXHTFB-UHFFFAOYSA-N 0.000 claims 1
- GCAJHGWOMWYLNL-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C=1C=NOC=1C GCAJHGWOMWYLNL-UHFFFAOYSA-N 0.000 claims 1
- DFZABDFGCIGGKC-UHFFFAOYSA-N [3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]azetidin-1-yl]-cyclopropylmethanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C1)CN1C(=O)C1CC1 DFZABDFGCIGGKC-UHFFFAOYSA-N 0.000 claims 1
- FFHNSAHWOCYDHQ-UHFFFAOYSA-N [5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridin-3-yl]-(4-hydroxypiperidin-1-yl)methanone Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C(C=1)=CN=CC=1C(=O)N1CCC(O)CC1 FFHNSAHWOCYDHQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- BVYVSUUHEINNDU-UHFFFAOYSA-N ethyl 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidin-1-yl]-2-methylpropanoate Chemical compound C1N(C(C)(C)C(=O)OCC)CC1C1=C(OCC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N BVYVSUUHEINNDU-UHFFFAOYSA-N 0.000 claims 1
- PADXZKBKBRMKAQ-UHFFFAOYSA-N ethyl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC1C1=C(OCC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N PADXZKBKBRMKAQ-UHFFFAOYSA-N 0.000 claims 1
- XHEKEHKYMSHBMN-UHFFFAOYSA-N ethyl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N XHEKEHKYMSHBMN-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- TYVCXOQGEWXXAE-UHFFFAOYSA-N methyl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidine-1-carboxylate Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)OC)C1 TYVCXOQGEWXXAE-UHFFFAOYSA-N 0.000 claims 1
- WOMUYKUYGVUOFW-UHFFFAOYSA-N methyl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC)CC1C1=C(OC)C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=CC(Cl)=C1C#N WOMUYKUYGVUOFW-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- YJYZWGGKAAEEJC-UHFFFAOYSA-N propan-2-yl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidine-1-carboxylate Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)OC(C)C)C1 YJYZWGGKAAEEJC-UHFFFAOYSA-N 0.000 claims 1
- DQRBEVSPBUBTPN-UHFFFAOYSA-N propan-2-yl 3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]azetidine-1-carboxylate Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(=O)OC(C)C)C1 DQRBEVSPBUBTPN-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000004089 sulfido group Chemical group [S-]* 0.000 claims 1
- ZDWVTAJNKPYTCP-UHFFFAOYSA-N tert-butyl 2-[3-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]azetidin-1-yl]-2-methylpropanoate Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1CN(C(C)(C)C(=O)OC(C)(C)C)C1 ZDWVTAJNKPYTCP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (50)
1. Spoj formule I:
[image]
ili njegova farmaceutski prihvatljiva soll, naznačen time, što:
X označava CR9 ili N;
W označava CR7 ili N;
Y označava CR8, CR8a ili N;
Z označava kemijsku vezu ili C(=O) grupu;
pod uvjetom da -W=Y-Z- označava -CR7=CR8, -N=CR8-, -CR7=CR8a-C(=O)-, -N=CR8a-C(=O)- ili -CR7=N-C(=O)-;
R1 označava C1-3 alkil grupu;
R2 označava halogenu, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C1-6 haloalkoksi, fenil ili 5-6-članu heteroaril grupu; i naznačen je time, što svaka navedena fenil i 5-6-člana heteroaril grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine halogena, OH, CN, C1-4 alkil, C1-4 alkoksi i C1-4 haloalkoksi grupa;
R3 označava Cy, -(C1-3 alkilen)-Cy, halogenu, CN, NO2, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, ORa, SRa, C(=O)Rb, C(=O)NRcRd, C(=O)ORa, OC(=O)Rb, OC(=O)NRcRd, NRcRd, NRcC(=O)Rb, NRc=C(=O)ORb, NRcC(=O)NRcRd, C(=NRe)Rb, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcS(=O)2Rb, NRcS(=O)2NRcRd, S(=O)2Rb ili S(=O)2NRcRd grupu; i naznačen je time, što svaka navedena C1-6 alkil, C2-6 alkenil i C2-6 alkinil grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R3a grupe;
R4 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R5 označava halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, C1-4 haloalkoksi ili ciklopropil grupu;
R6 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R7 označava H ili C1-4 alkil grupu;
R8 označava H, halogenu, -OH, -CN, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, Cy2, -(C1-3 alkilen)-Cy2, ORa2, SRa2, C(=O)Rb2, C(=O)NRc2Rd2, C(=O)ORa2, OC(=O)Rb2, OC(=O)NRc2Rd2, NRc2Rd2, NRc2C(=O)Rb2, NRc2C(=O)ORb2, NRc2C(=O)NRc2Rd2, C(=NRe)Rb2, C(=NRe)NRc2Rd2, NRc2C(=NRe)NRc2Rd2, NRc2S(=O)Rb2, NRc2S(=O)2NRc2Rd2, S(=O)Rb2, S(=O)2Rb2 ili S(=O)2NRc2Rd2 grupu; i naznačen je time, što svaka navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
R8a označava H, halogenu, -CN, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, Cy2, -(C1-3 alkilen)-Cy2, C(=O)Rb2, C(=O)NRc2Rd2, C(=O)ORa2, NRc2Rd2, NRc2C(=O)Rb2, NRc2C(=O)ORb2, NRc2C(=O)NRc2Rd2, NRc2S(=O)Rb2, NRc2S(=O)2NRc2Rd2, S(=O)Rb2, S(=O)2Rb2 ili S(=O)2NRc2Rd2grupu; i naznačen je time, što svaka navedena C1-6 alkil, C2-6alkenil, C2-6 alkinil grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
R9 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R10 označava H ili C1-4 alkil grupu;
svaki Ra, Rb, Rc i Rd je nezavisno izabran iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil i Cy grupa; i naznačen je time, što svaka navedena C1-6 alkil, C2-6 alkenil i C2-6 alkinil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R3b grupe;
ili Rc i Rd zajedno sa atomom N za koji su vezani može obrazovati 4-, 5-, 6- ili 7-članu heterocikloalkil grupu koja dalje može biti supstituirana sa -OH ili C1-3 alkil grupom;
svaki Re je nezavisno izabran iz grupe koju čine H, CN, OH, C1-4 alkil i C1-4 alkoksi grupa;
svaki Cy je nezavisno izabran iz grupe koju čine C3-7 cikloalkil, 4-10-člana heterocikloalkil, fenil, naftil i 5-10-člana heteroaril grupa od kojih svaka može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R3b grupe;
svaki R3a je nezavisno izabran iz grupe koju čine halogena, CN, NO2, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, ORa1, SRa1, C(=O)Rb1, C(=O)NRc1Rd1, C(=O)ORa1, OC(=O)Rb1, OC(=O)NRc1Rd1, NRc1Rd1, NRc1C(=O)Rb1, NRc1C(=O)ORb1, NRc1C(=O)NRc1Rd1, C(=NRe)Rb1, C(=NRe)NRc1Rd1, NRc1C(=NRe)NRc1Rd1, NRc1S(=O)Rb1, NRc1S(=O)2NRc1Rd1, S(=O)2Rb1 i S(=O)2NRc1Rd1 grupa; i naznačen je time, što navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
svaki R3b je nezavisno izabran iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, NO2, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, ORa1, SRa1, C(=O)Rb1, C(=O)NRc1Rd1, C(=O)ORa1, OC(=O)Rb1, OC(=O)NRc1Rd1, NRc1Rd1, NRc1C(=O)Rb1, NRc1C(=O)ORb1, NRc1C(=O)NRc1Rd1, C(=NRe)Rb1, C(=NRe)NRc1Rd1, NRc1C(=NRe)NRc1Rd1, NRc1S(=O)Rb1, NRc1S(=O)2NRc1Rd1, S(=O)Rb1, S(=O)2Rb1 i S(=O)2NRc1Rd1 grupa; i naznačen je time, što navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil grupa može biti supstituirane sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
svaka Cy1 grupa je nezavisno izabrana iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa, pri čemu svaka od navedenih grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa; i naznačen je time, što svaka navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
ili Rc1 i Rd1 zajedno sa atomom N za koji su vezani može obrazovati 4-, 5-, 6- ili 7-članu heterocikloalkil grupu koja dalje može biti supstituirana sa -OH ili C1-3 alkil grupom;
svaki Cy2 je nezavisno izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil, 5-6-člana heteroaril ili 9-10-člana biciklična heteroaril grupa od kojih svaka dalje može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
svaki Ra2, Rb2, RC2 i Rd2 je nezavisno izabran iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa; i naznačen je time, što svaka od navedenih C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-članih heterocikloalkil, fenil i 5-6-članih heteroaril grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
ili Rc2 i Rd2 zajedno sa atomom N za koji su vezani može obrazovati 4-, 5-, 6- ili 7-članu heterocikloalkil grupu koja dalje može biti supstituirana sa -OH ili C1-3 alkil grupom; i
svaki R11 je nezavisno izabran iz grupe koju čine OH, NO2, CN, halogena, C1-3 alkil, C2-3alkenil, C2-3 alkinil, C1-3 haloalkil, cijano-C1-3 alkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C3-7cikloalkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, tio, C1-3 alkiltio, C1-3 alkilsulfinil, C1-3 alkilsulfonil, karbamil, C1-3alkilkarbamil, di(C1-3 alkil)karbamil, karboksi, C1-3 alkilkarbonil, C1-4 alkoksikarbonil, C1-3 alkilkarbonilamino, C1-3 alkilsulfonilamino, aminosulfonil, C1-3alkilaminosulfonil, di(C1-3 alkil)aminosulfonil, aminosulfonilamino, C1-3 alkilaminosulfonilamino, di(C1-3 alkil)aminosulfonilamino, aminokarbonilamino, C1-3alkilamino-karbonilamino i di(C1-3 alkil)aminokarbonilamino grupa;
i naznačen time, što atomi ugljika koji formiraju prsten i heteroatomi heterocikloalkilnih grupa mogu biti supstituirani sa okso ili sulfido grupama.
2. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva soll, naznačen time, što
[image]
[image]
ostatak označava:
[image]
ili
[image]
3. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R1 označava metil grupu.
4. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R2 označava C1-6 alkil, C1-3 alkoksi ili fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata.
5. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time što je svaki Ra, Rb, Rc i Rd nezavisno izabran iz grupe koju čine H, C1-6 alkil, i C1-6haloalkil grupa.
6. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R3 označava Cy grupu.
7. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R3 označava C(=O)NRcRd grupu; naznačenu time, što je svaki Rc i Rd nezavisno izabran iz grupe koju čine radikali C1-6alkila.
8. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time, što:
svaki Cy označava radikal nezavisno izabran iz grupe koju čine radikal prstena azetidina, radikal prstena pirazola, radikal prstena piridina, radikal prstena pirimidina, radikal prstena fenila, pri čemu svaki od navedenih radikala može biti supstituiran sa jednim R3bizabranim iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Ra1, S(=O)Rb1 i S(=O)2NRc1Rd1 grupa; pri čemu svaka navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i naznačen je time, što navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe; i
svaki R11 nezavisno označava OH ili C1-3 alkoksi grupu.
9. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R4 označava halogenu, CN ili C1-4 alkil grupu.
10. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R5 označava halogenu ili CN grupu.
11. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R6 označava H.
12. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R7 označava H.
13. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R8 označava H, halogenu, CN, metil ili Cy2 grupu; i naznačen time, što je Cy2 izabrano iz grupe koju čine ciklopropil, fenil grupa, sistem prstena pirazola, sistem prstena piridina ili sistem prstena pirimidina, pri čemu svaka navedena grupa može biti supstituirana sa 1 R11 izabranim iz grupe koju čine OH, CN, fluoro, metil, 2-hidroksietil, dimetilkarbamil, amino, metilkarbamil i dimetilkarbamil grupa.
14. Spoj iz bilo kojeg od patentnih zahtjeva 1-7 i 9-12, ili njegova farmaceutski prihvatljiva sol, naznačen time, što svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu.
15. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R8a označava H, halogenu, -CN, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6haloalkil ili Cy2 grupu.
16. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R9 označava H.
17. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R10 označava H.
18. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, što
[image]
ostatak označava:
[image]
[image]
ili
R1 označava metil grupu;
R2 označava C1-3 alkoksi grupu;
R3 označava Cy grupu;
Cy označava grupu izabranu od C3-7 cikloalkil, 4-7-člane heterocikloalkil, fenil i 5-6 člane heteroaril grupe, pri čemu svaka od navedenih grupa može biti supstituirana sa 1 ili 2 R3b nezavisno izabrana iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Rd1, S(=O)Rb1 i S(=O)2NRc1Rd1 grupa; Cy je naznačen i time, što navedena C1-6alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i naznačen je time, što navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu;
svaki R6, R7, R9 i R10 označava H;
R8 označava H, halogenu, CN, C1-6 alkil ili Cy2grupu; i naznačen je time, što je Cy2 izabran iz grupe koju čine C3-6 cikloalkil, fenil, 5-6 člana heteroaril i 4-7 člana heterocikloalkil grupa, naznačene time, što svaka od navedenih grupa može biti supstituirana sa 1 R11 grupom;
R8a označava H ili halogenu grupu; i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu.
19. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, što
[image]
[image]
ostatak označava:
[image]
ili
[image]
R1 označava metil grupu;
R2 označava fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata;
R3 označava C(=O)NRcRd grupu; pri čemu je svaki Rc i Rd nezavisno izabran iz grupe koju čine radikali C1-6 alkila;
Cy je izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6 člana heteroaril grupa, pri čemu svaka od navedenih može biti supstituirana sa 1 ili 2 R3b nezavisno izabrana iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Ra1, S(=O)Rb1 i S(=O)2NRc1Rd1; i naznačen je time, što navedena C1-6alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil, i C1-6 haloalkil grupa; i naznačen je time, što navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu;
svaki R6, R7, R9 i R10 označava H;
R8 označava H, halogenu, CN, C1-6 alkil ili Cry2 grupu; i naznačen je time, što je Cry2 izabran iz grupe koju čine C3-6 cikloalkil, fenil, 5-6 člana heteroaril i 4-7 člana heterocikloalkil grupa od kojih svaka može biti supstituirana sa 1 R11 grupe;
R8a označava H ili radikal halogenog elementa; i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C 1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu.
20. Spoj iz bilo kojeg od patentnih zahtjeva 1-10, 13-14 i 18-19 formule II:
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
21. Spoj iz patentnog zahtjeva 1:
[image]
a) formule IIa:
[image]
ili njegova farmaceutski prihvatljiva sol; naznačen time, što:
R2 označava C1-6 alkil, C1-3 alkoksi ili fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata;
R3 označava Cy ili C(=O)NRcRdgrupu; naznačenu time, što je svaki Rc i Rc nezavisno izabran iz grupe koju čine radikali C1-6 alkila;
Cy je izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa, pri čemu svaka od navedenih grupa može biti supstituirana sa 1 ili 2 R3b koji su nezavisno izabrani iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Rd1, S(=O)Rb1 i S(=O)2NRc1Rd1 grupa, i pri čemu navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i pri čemu navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu;
R8 označava H, halogenu, CN, C1-6 alkil ili Cy2 grupu; i pri čemu je Cy2 izabran iz grupe koju čine C3-6 cikloalkil, fenil, 5-6-člana heteroaril i 4-7-člana heterocikloalkil grupa od kojih svaka može biti supstituirana sa 1 R11 grupom; i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu; ili
[image]
b) formule IIIa:
[image]
ili njegova farmaceutski prihvatljiva sol; naznačen time, što:
R2 označava C1-6 alkil, C1-3 alkoksi ili fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata;
R3 označava Cy ili C(=O)NRc Rd grupu; naznačenu time, što je svaki Rc i Rd nezavisno izabran iz grupe koju čine radikali C1-6 alkila;
Cy je izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa, pri čemu svaka od navedenih grupa može biti supstituirana sa 1 ili 2 R3b nezavisno izabrana iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Rd1, S(=O)Rb1 i S(=O)2NRc1Rd1grupa; i pri čemu navedena C1-6alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i pri čemu navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu; i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu; ili
[image]
c) formule IVa:
[image]
ili njegova farmaceutski prihvatljiva sol; naznačen time, što:
R2 označava C1-6 alkil, C1-3 alkoksi ili fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata;
R3 označava Cy ili C(=O)NRc Rd grupu; pri čemu je svaki Rc i Rc nezavisno izabran iz grupe koju čine radikali C1-6 alkila;
Cy je izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa, pri čemu svaka od njih može biti supstituirana sa 1 ili 2 R3b nezavisno izabrana iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Rd1, S(=O)Rb1 i S(=O)2NRc1Rd1; navedena C1-6alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i pri čemu što navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu; i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu; ili
[image]
[image]
d) spoj formule Va:
[image]
ili njegova farmaceutski prihvatljiva sol; naznačen time, što:
R2 označava C1-6 alkil, C1-3 alkoksi ili fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata;
R3 označava Cy ili C(=O)NRcRd grupu; pri čemu je svaki Rc i Rc nezavisno izabran iz grupe koju čine C1-6 alkil radikali;
Cy je izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa i pri čemu svaka navedena grupa može biti supstituirana sa 1 ili 2 R3b koji su nezavisno izabrani iz grupe koju čine Cy1, -(C1-3 alkilen)-Cy1, halogena, CN, OH, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C(=O)Rb1, C(=O)NRc1Rd1, S(=O)Rb1 i S(=O)2NRc1Rd1 grupa; i pri čemu navedena C1-6alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
Cy1 označava C3-6 cikloalkil ili 4-7-članu heterocikloalkil grupu;
svaki Ra1, Rb1, Rc1 i Rd1 je nezavisno izabran iz grupe koju čine H, C1-6 alkil i C1-6 haloalkil grupa; i pri čemu navedena C1-6 alkil grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11grupe;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu ili CN grupu;
R8 označava H, halogenu, CN, C1-6 alkil ili Cy2 grupu; pri čemu je Cy2 grupa izabrana iz grupe koju čine C3-6 cikloalkil, fenil, 5-6-člana heteroaril i 4-7-člana heterocikloalkil grupa od kojih svaka može biti supstituirana sa 1 R11 grupom;
i
svaki R11 nezavisno označava OH, CN, halogenu, C1-3 alkil, C1-3 haloalkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, karbamil, C1-3 alkilkarbamil ili di(C1-3 alkil)karbamil grupu.
22. Spoj iz patentnog zahtjeva 21, ili njegova farmaceutski prihvatljiva sol, naznačen time, što:
a) R2 označava C1-3 alkoksi grupu; a R3 označava Cy grupu; ili
b) R2 označava fenil grupu; pri čemu navedena fenil grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine radikali halogenih elemenata; dok R3 označava radikal C(=O)NRcRd; pri čemu je svaki Rc i Rc nezavisno izabran iz grupe koju čine radikaliC1-6alkila.
23. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 22, naznačen time, što R2 ili R3 sadrži najmanje jednu cikličnu grupu.
24. Spoj iz patentnog zahtjeva 1:
a) izabran iz grupe koju čine:
1-{1-[5-kloro-3-(1-izopropilazetidin-3-il)-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[3-(1-acetilazetidin-3-il)-5-kloro-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-2-metoksi-4-metil-3-(1-propionilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{5-kloro-3-[1-(ciklopropilmetil)azetidin-3-il]-2-metoksi-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-2-metoksi-4-metil-3-(1-metilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-3-(1-etilazetidin-3-il)-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-3-(1-izobutilazetidin-3-il)-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[3-(1-sek-butilazetidin-3-il)-5-kloro-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{5-kloro-2-metoksi-3-[1-(2-metoksietil)azetidin-3-il]-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-metilazetidin-1-karboksamid;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin 2-karboksamid;
5-{3-[1-(4-amino-7H-pirolo[2,3-d]pirimidin-7-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
1-{1-[5-kloro-4-fluoro-3-(1-izopropilazetidin-3-il)-2-metoksifenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-jod-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-metilpikolinamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-(2-hidroksietil)piridin-2-karboksamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-(2-hidroksietil)-N-metilpiridin-2-karboksamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-1H-pirazol-1-il)etanol;
3’-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5'-kloro-3-fluoro-2'-metoksi-N,N,6'-trimetilbifenil-4-karboksamid;
3’-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5'-kloro-3-fluoro-2'-metoksi-N,6'-dimeti-4-karboksamid;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-(2-hidroksietil)pikolinamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-(2-hidroksietil)-N-metilpiridin-2-karboksamid;
5-{3-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-amino-8-(1-{5-kloro-2-metoksi-4-metil-3-[5-(metilsulfonil)piridin-3-il]fenil}etil)pirido[2,3-d]pirimidin-5(8H)-on;
5-{3-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-2-metoksi-6-metilfenil}nikotinonitril;
4-amino-8-[1-(5-kloro-2-metoksi-4-metil-3-piridin-3-ilfenil)etil]pirido[2,3-d]pirimidin-5 (8H)-on;
4-amino-8-[1-(5-kloro-2-metoksi-4-metil-3-pirimidin-5-ilfenil)etil]pirido[2,3-d]pirimidin-5 (8H)-on;
3’-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5'-kloro-2'-metoksi-N,N,6'-trimetilbifenil-3-karboksamid;
4-amino-8-{1-[5-kloro-3-(5-fluoropiridin-3-il)-2-metoksi-4-metilfenil]etil}pirido[2,3-d]pirimidin-5(8H)-on;
3’-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5'-kloro-2'-metoksi-N,N,6'-trimetilbifenil-3-sulfonamid;
5-{3-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-metilpiridin-2-karboksamid;
4-amino-8-{1-[5-kloro-3-(1-izopropilazetidin-3-il)-2-metoksi-4-metilfenil]etil}pirido[2,3-d]pirimidin-5(8H)-on;
4-amino-8-{1-[5-kloro-2-etoksi-3-(1-izopropilazetidin-3-il)-4-metilfenil]etil}pirido[2,3-d]pirimidin-5(8H)-on;
5-{3-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
6-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-4-kloro-N-etil-3’,5'-difluoro-3-metilbifenil-2-karboksamid;
4-{3-[1-(4-amino-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-{3-[1-(4-amino-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-(2-hidroksietil)piridin-2-karboksamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-cijano-2-metoksi-6-metilfenil}-N-(2-hidroksietil)-N-metilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[4,3-c]piridin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-5-metil-7-pirolo[2,3-d]pirimidin-7-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[5-(metilsulfonil)piridin-3-il]benzonitril;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-6-cijano-2-etoksi-fenil)-N,N-dimetilpikolinamid;
5-{3-[1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-6-cijano-2-etoksifenil}-N,N-dimetilpiridin-2-karboksamid;
4-(1-(4-amino-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil)-6-kloro-3-etoksi-2-(5-(metilsulfonil)piridin-3-il)benzonitril;
5-(3-{1-[4-amino-3-(3-fluorofenil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(1H-pirazol-4-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(1-metil-1H-pirazol-4-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(1-metil-1H-pirazol-3-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(1H-pirazol-3-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-[3-(1-{4-amino-3-[1-(2-hidroksietil)-1H-pirazol-4-il]-1H-pirazolo[3,4-d]pirimidin-1-il}etil)-5-kloro-2-etoksi-6-metilfenil]-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-ciklopropil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-cijano-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(4-fluorfenil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-{4-amino-1-[1-(5-kloro-3-{6-[(dimetilamino)karbonil]piridin-3-il}-2-etoksi-4-metilfenil)etil]-1H-pirazolo[3,4-d]pirimidin-3-il}-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(5-cijanopiridin-3-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(2-aminopirimidin-5-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-{6-[(metilamino)karbonil]piridin-3-il}-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-piridin-4-il-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-piridin-3-il-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-{5-[(dimetilamino)karbonil]piridin-3-il}-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
1-{1-[5-kloro-2-metoksi-4-metil-3-(1-oksetan-3-ilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{5-kloro-2-metoksi-4-metil-3-[1-(tetrahidro-2H-piran-4-il)azetidin-3-il]fenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilnikotinamid; i
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih spojeva; ili
b) izabran iz grupe koju čine:
1-{1-[5-kloro-4-fluoro-3-(1-izopropilazetidin-3-il)-2-metoksifenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-fluoro-2-metoksifenil}azetidin-1-il)propan-2-ol;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-fluoro-2-metoksifenil}azetidin-1-il)propan-2-ol;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-fluoro-2-metoksifenil}azetidin-1-il)-2-metilpropan-2-ol;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-fluoro-2-metoksifenil}azetidin-1-il)etanol;
1-{1-[5-kloro-4-fluoro-2-metoksi-3-(1-oksetan-3-ilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-4-fluoro-3-(1-izopropilazetidin-3-il)-2-metoksifenil]etil}-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-6-fluoro-2-metoksifenil)azetidin-1-il]etanol;
1-{1-[5-kloro-4-fluoro-2-metoksi-3-(1-metilazetidin-3-il)fenil]etil}-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2S)-1-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-6-H-2-metoksifenil)azetidin-1-il]propan-2-ol;
5-(1-(4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-2-fluoro-3-(1-((S)-2-hidrokipropil)azetidin-3-il)-4-metoksibenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-2-fluoro-3-[1-(2-hidroksietil)azetidin-3-il]-4-metoksibenzonitril;
5-[3-(1-{4-amino-3-[(3R)-3-hidroksibut-1-in-1-il]-1H-pirazolo[3,4-d]pirimidin-1-il}etil)-5-kloro-2-etoksi-6-metilfenil]-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
5-[3-(1-{4-amino-3-[(3S)-3-hidroksibut-1-in-1-il]-1H-pirazolo[3,4-d]pirimidin-1-il}etil)-5-kloro-2-etoksi-6-metilfenil]-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
5-{3-[1-(4-amino-3-etil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
5-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
5-(3-{1-[4-amino-3-(hidroksimetil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
5-[3-(1-{4-amino-3-[(metilamino)metil]-1H-pirazolo[3,4-d]pirimidin-1-il}etil)-5-kloro-2-etoksi-6-metilfenil]-N,N-dimetilpiridin-2-karboksamid tris(trifluoroacetat);
5-[3-(1-{4-amino-3-[(dimetilamino)metil]-1H-pirazolo[3,4-d]pirimidin-1-il}etil)-5-kloro-2-etoksi-6-metilfenil]-N,N-dimetilpiridin-2-karboksamid tris(trifluoroacetat);
5-(3-{1-[4-amino-3-(fluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
3-{1-[4-amino-3-(1H-pirazol-4-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-{1-[4-amino-3-(3-fluoro-5-hidroksifenil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-(1-(4-amino-3-(2-aminobenzo[d]oksazol-5-il)-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-{1-[4-amino-3-(2-amino-1,3-benzotiazol-6-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-{1-[4-amino-3-(1H-pirolo[2,3-b]piridin-5-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-{1-[4-amino-3-(1H-indazol-6-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
3-{1-[4-amino-3-(1H-indol-5-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-N-etil-6-metilbenzamid;
1-{1-[5-kloro-2-etoksi-3-(1-izopropilazetidin-3-il)-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin bis(trifluoroacetat);
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)etanol bis(trifluoroacetat);
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)propan-2-ol bis(trifluoroacetat);
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)propan-2-ol;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)-2-metilpropan-2-ol;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)-1-oksopropan-2-ol trifluoroacetat;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}azetidin-1-il)-1-oksopropan-2-ol;
1-[1-(5-kloro-2-etoksi-4-metil-3-{1-[(1-metil-1H-pirazol-4-il)karbonil]azetidin-3-il}fenil)etil]-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin trifluoroacetat;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)propan-2-ol;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)propan-2-ol;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)etanol;
(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)acetonitril;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)propannitril;
1-(1-{5-kloro-2-metoksi-4-metil-3-[1-(tetrahidrofuran-3-il)azetidin-3-il]fenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{5-kloro-2-metoksi-4-metil-3-[1-(2,2,2-trifluoroetil)azetidin-3-il]fenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
3-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-1,1,1-trifluoropropan-2-ol;
(2R)-2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-N-metilpropanamid trifluoroacetat;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)acetamid;
1-(1-{5-kloro-3-[1-(2,2-difluor-etil)azetidin-3-il]-2-metoksi-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-3,3,3-trifluoropropan-1-ol;
1-(1-{5-kloro-3-[1-(2-fluoro-1-metiletil)azetidin-3-il]-2-metoksi-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2R)-3-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-1,1,1-trifluoropropan-2-ol;
(2S)-3-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-1,1,1-trifluoropropan-2-ol;
1-[1-(5-kloro-2-metoksi-4-metil-3-{1-[(1-metil-1H-pirazol-4-il)karbonil]azetidin-3-il}fenil)etil]-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-1-oksopropan-2-ol;
1-(1-{5-kloro-3-[1-(ciklopropilkarbonil)azetidin-3-il]-2-metoksi-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-[1-(5-kloro-2-metoksi-4-metil-3-{1-[(5-metilizoksazol-4-il)karbonil]azetidin-3-il}fenil)etil]-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-1-oksopropan-2-ol trifluoroacetat;
1-[(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)karbonil]ciklopropanol;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-2-metil-1-oksopropan-2-ol;
1-(1-{5-kloro-2-metoksi-4-metil-3-[1-(1H-pirazol-4-ilkarbonil)azetidin-3-il]fenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
[3-(3-{1-[4-amino-3-(1-metil-1H-pirazol-4-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-metoksi-6-metilfenil)azetidin-1-il]acetonitril bis(trifluoroacetat);
[3-(3-{1-[4-amino-3-(1H-pirazol-4-il)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-metoksi-6-metilfenil)azetidin-1-il]acetonitril;
1-{1-[5-kloro-3-(1-izopropilazetidin-3-il)-2-metoksi-4-metilfenil]etil}-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-(1-izopropilazetidin-3-il)-4-metoksi-2-metilbenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-4-metoksi-2-metil-3-[1-(2,2,2-trifluoroetil)azetidin-3-il]benzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-[1-(2-hidroksietil)azetidin-3-il]-4-metoksi-2-metilbenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-{1-[(2S)-2-hidroksipropil]azetidin-3-il}-4-metoksi-2-metilbenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-{1-[(2R)-2-idroksipropil]azetidin-3-il}-4-metoksi-2-metilbenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-[1-(2-hidroksi-2-etilpropil)azetidin-3-il]-4-metoksi-2-metilbenzonitril;
(2S)-2-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-cijano-2-metoksi-6-metilfenil)azetidin-1-il]-N-metilpropanamid;
(2R)-2-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-cijano-2-metoksi-6-metilfenil)azetidin-1-il]-N-metilpropanamid;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-[1-(2,2-difluor-etil)azetidin-3-il]-4-metoksi-2-metilbenzonitril;
5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-3-{1-[(2S)-2-hidroksipropil]azetidin-3-il}-4-metoksi-2-metilbenzonitril;
3-(1-acetilazetidin-3-il)-5-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-4-metoksi-2-metilbenzonitril;
1-{1-[5-kloro-2-etoksi-4-fluoro-3-(1-izopropilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)-2-metilpropan-2-ol;
1-(1-{5-kloro-2-etoksi-4-fluoro-3-[1-(2,2,2-trifluoroetil)azetidin-3-il]fenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)propan-2-ol;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)propan-2-ol;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)etanol;
1-{1-[5-kloro-2-etoksi-4-fluoro-3-(1-metilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-2-etoksi-3-(1-etilazetidin-3-il)-4-fluorofenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{5-kloro-3-[1-(2,2-difluor-etil)azetidin-3-il]-2-etoksi-4-fluorofenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)acetamid;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}azetidin-1-il)propan-2-ol;
1-{1-[5-kloro-2-etoksi-4-fluoro-3-(1-izopropilazetidin-3-il)fenil]etil}-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-2-etoksi-4-fluoro-3-(1-metilazetidin-3-il)fenil]etil}-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-fluorofenil)azetidin-1-il]etanol;
1-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-metoksi-6-fluorofenil)azetidin-1-il]-2-metilpropan-2-ol;
(2S)-1-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-fluorofenil)azetidin-1-il]propan-2-ol;
(2R)-1-[3-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-fluorofenil)azetidin-1-il]propan-2-ol;
(2R)-2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)propan-1-ol;
(2S)-2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)propan-1-ol;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-2-metilpropan-2-ol;
(2R)-2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-N,N-dimetil;
(2S)-2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-N,N-dimetil;
[1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)ciklobutil]acetonitril;
3-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}azetidin-1-il)-2-metilpropannitril;
1-{1-[5-kloro-2-metoksi-4-metil-3-(1-metilpiperidin-4-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}piperidin-1-il)-2-metilpropan-2-ol;
5-(3-{1-[4-amino-3-(cijanometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}ciklobutanol trifluoracetat;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N,N-dimetilpikolinamid bis(2,2,2-trifluoroacetat);
1-(1-(5-kloro-2-metoksi-4-metil-3-(pirimidin-5-il)fenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-(3-(2-aminopirimidin-5-il)-5-kloro-2-metoksi-4-metilfenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)nikotinonitril;
1-(1-(3-(6-aminopiridin-3-il)-5-kloro-2-metoksi-4-metilfenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-(5-kloro-2-metoksi-4-metil-3-(5-(metilsulfonil)piridin-3-il)fenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-metilpikolinamid;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-ciklopropil-N-metilnikotinamid bis(2,2,2-trifluoroacetat);
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N-(2-hidroksietil)-N-metilnikotinamid;
1-[(5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}piridin-3-il)karbonil]piperidin-4-ol;
1-[(5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}piridin-3-il)karbonil]azetidin-3-karbonitril;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-(2-aminoetil)-N-metilnikotinamid;
3-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N-metilpropanamid 2,2,2-trifluoroacetat;
3-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N,N-dimetil;
1-(1-(5-kloro-2-metoksi-4-metil-3-(1-(1-metilpiperidin-4-il)-1H-pirazol-4-il)fenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-{3-[1-(1-acetilpiperidin-4-il)-1H-pirazol-4-il]-5-kloro-2-metoksi-4-metilfenil}etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-[1-(5-kloro-3-{1-[2-(dimetilamino)etil]-1H-pirazol-4-il}-2-metoksi-4-metilfenil)etil]-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-[(5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}piridin-2-il)amino]-etanol;
1-(1-(5-kloro-3-(6-(dimetilamino)piridin-3-il)-2-metoksi-4-metilfenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-(5-kloro-3-(2-(dimetilamino)piridin-4-il)-2-metoksi-4-metilfenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)piridin-2-il)azetidin-3-ol;
2-(5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)piridin-2-iloksi) etanol;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-(2,2-dif)-6-metilfenil)-N,N-dimetilpikolinamid bis(2,2,2-trifluoroacetat);
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-(ciklopropilmetoksi)-6-metilfenil)-N,N-dimetilpikolinamid bis(2,2,2-trifluoroacetat);
5-(3-{1-[4-amino-3-(difluorometil)-1H-pirazolo[3,4-d]pirimidin-1-il]etil}-5-kloro-2-metoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid;
1-[1-(5-kloro-3-ciklopropil-2-metoksi-4-metilfenil)etil]-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[5-kloro-3-(ciklopropilmetil)-2-metoksi-4-metilfenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}acetonitril;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpikolinamid bis(2,2,2-trifluoroacetat);
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilnikotinamid;
1-(1-(5-kloro-2-etoksi-4-metil-3-(1-metil-1H-pirazol-4-il)fenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-(1-(5-kloro-2-etoksi-4-metil-3-(5-(metilsulfonil)piridin-3-il)fenil)etil)-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
5-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-N-metilpikolinamid;
4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-N,N-dimetilpikolinamid bis(2,2,2-trifluoroacetat);
4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-N,N-dimetilpikolinamid;
4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-N-(2-hidroksietil)-N-metilpikolinamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-1H-pirazol-1-il)acetamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-1H-pirazol-1-il)-N-metilacetamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-metilfenil)-1H-pirazol-1-il)-N,N-dimetilacetamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-1H-pirazol-1-il)-N,N-dimetilacetamid;
2-(4-(3-(1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-metoksi-6-metilfenil)-1H-pirazol-1-il)-N,N-dimetil;
6-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}-N,N-dimetilnikotinamid bis(trifluoroacetat);
5-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-4-metoksi-2-metil-3-(1-metil-1H-pirazol-4-il)benzonitril;
5-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-4-etoksi-2-metil-3-(1-metil-1H-pirazol-4-il)benzonitril;
3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-2-azetidin-3-il-6-kloro-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(1-metilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]piramidin-1-il)etil]-6-kloro-3-etoksi-2-(1-etilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(1-izopropilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(1-izobutilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilmetil)azetidin-3-il]-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-ciklobutilazetidin-3-il)-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksietil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-{1-[(2S)-2-hidroksipropil]azetidin-3-il}benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-{1-[(2R)-2-hidroksipropil]azetidin-3-il}benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksi-2-metilpropil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksi-1-metiletil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-metoksietil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-{1-[2-metoksi-1-(metoksimetil)etil]azetidin-3-il}benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(tetrahidrofuran-3-il)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(tetrahidro-2H-piran-4-il)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(tetrahidrofuran-3-ilmetil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(tetrahidro-2H-piran-4-ilmetil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2,2,2-trifluoroetil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(3,3,3-trifluoropropil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(cijanometil)azetidin-3-il]-3-etoksibenzonitril;
terc-butil 2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-1-il)-2-metilpropanoat;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksi-1,1-dimetiletil)azetidin-3-il]benzonitril;
etil 2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksifenil}azetidin-1-il)-2-metilpropanoat;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksifenil}azetidin-1-il)-2-metilpropanamid;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksifenil}azetidin-1-il)-N,2-dimetilpropanamid;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksifenil}azetidin-1-il)-N,N,2-trimetilpropanamid;
2-(1-acetilazetidin-3-il)-4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(1-propionilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(1-izobutirilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(2,2-dimetilpropanoil)azetidin-3-il]-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilkarbonil)azetidin-3-il]-3-etoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksi-2-metilpropanoil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(metilsulfonil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(etilsulfonil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(izopropilsulfonil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilsulfonil)azetidin-3-i]-3-etoksibenzonitril;
metil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-1-karboksilat;
etil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-1-karboksilat;
izopropil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-1-karboksilat;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N-(terc-butil)azetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N-metilazetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N-etilazetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N,N-dimetilazetidin-1-karboksamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksietil)azetidin-3-il]benzonitril-d4;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-2-azetidin-3-il-6-kloro-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-(1-metilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-etilazetidin-3-il)-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-izopropilazetidin-3-il)-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-izobutilazetidin-3-il)-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilmetil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-ciklobutilazetidin-3-il)-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(2-hidroksietil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-{1-[(2S)-2-hidroksipropil]azetidin-3-il}-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-{1-[(2R)-2-hidroksipropil]azetidin-3-il}-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(2-hidroksi-2-metilpropil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(2-hidroksi-1-metiletil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-(1-oksetan-3-ilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[1-(tetrahidrofuran-3-il)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[1-(tetrahidro-2H-piran-4-il)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[1-(tetrahidrofuran-3-ilmetil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[1-(tetrahidro-2H-piran-4-ilmetil)azetidin-3-il]benzonitril;
2-(1-acetilazetidin-3-il)-4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-(1-propionilazetidin-3-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-(1-izobutirilazetidin-3-il)-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilkarbonil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[1-(metilsulfonil)azetidin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(etilsulfonil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(izopropilsulfonil)azetidin-3-il]-3-metoksibenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(ciklopropilsulfonil)azetidin-3-il]-3-metoksibenzonitril;
metil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}azetidin-1-karboksilat;
etil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}azetidin-1-karboksilat;
izopropil 3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}azetidin-1-karboksilat;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}-N-(terc-butil)azetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}azetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}-N-metilazetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}-N-etilazetidin-1-karboksamid;
3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}-N,N-dimetilazetidin-1-karboksamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-2-[1-(2-hidroksietil)azetidin-3-il]-3-metoksibenzonitril-d4;
1-{1-[4,5-dikloro-3-(1-etilazetidin-3-il)-2-metoksifenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
1-{1-[4,5-dikloro-3-(1-izopropilazetidin-3-il)-2-metoksifenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
2-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5,6-dikloro-2-metoksifenil}azetidin-1-il)etanol;
(2S)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5,6-dikloro-2-metoksifenil}azetidin-1-il)propan-2-ol;
(2R)-1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5,6-dikloro-2-metoksifenil}azetidin-1-il)propan-2-ol;
1-(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5,6-dikloro-2-metoksifenil}azetidin-1-il)-2-metilpropan-2-ol;
1-{1-[4,5-dikloro-2-metoksi-3-(1-oksetan-3-ilazetidin-3-il)fenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
(3-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5,6-dikloro-2-metoksifenil}azetidin-1-il)acetonitril;
1-{1-[3-(1-acetilazetidin-3-il)-4,5-dikloro-2-metoksifenil]etil}-3-metil-1H-pirazolo[3,4-d]pirimidin-4-amin;
4-[1-(4-amino-5-metil-7H-pirolo[2,3-d]pirimidin-7-il)etil]-6-kloro-3-etoksi-2-(1-izopropilazetidin-3-il)benzonitril;
4-[1-(4-amino-5-metil-7H-pirolo[2,3-d]pirimidin-7-il)etil]-6-kloro-3-etoksi-2-[1-(2-hidroksietil)azetidin-3-il]benzonitril;
4-[1-(4-amino-5-metil-7H-pirolo[2,3-d]pirimidin-7-il)etil]-6-kloro-3-etoksi-2-{1-[(2S)-2-hidroksipropil]azetidin-3-il}benzonitril;
5-{3-[1-(4-amino-5-metil-7H-pirolo[2,3-d]pirimidin-7-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid bis(trifluoroacetat);
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-metoksifenil}-N,N-dimetilpiridin-2-karboksamid;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-cijano-2-etoksi-5-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-[-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)-etil]-2-{1-[(2S)-2-hidroksipropil]azetidin-3-il}-3-metoksi-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[6-(1-hidroksi-1-metiletil)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-metoksi-6-metil-2-[5-(metilsulfonil)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-pirolidin-1-ilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(3-metoksiazetidin-1-il)benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-2-(1-izopropilazetidin-3-il)-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-2-[1-(2-hidroksi-2-metilpropil)azetidin-3-il]-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-2-[1-(2-hidroksi-2-metilpropanoil)azetidin-3-il]-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-2-{1-[(2S)-2-hidroksipropil]azetidin-3-il}-6-metilbenzonitril;
4-[-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-2-[1-(2-hidroksietil)azetidin-3-il]-6-metilbenzonitril;
4-[-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-2-[1-(2-hidroksi-2-metilpropil)azetidin-3-il]-3-metoksi-6-metilbenzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-pirimidin-5-ilbenzonitril;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}nikotinonitril;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N,N-dimetilnikotinamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-metoksi-2-[5-(metilsulfonil)piridin-3-il]benzonitril;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N-metilpiridin-2-karboksamid;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}-N,N-dimetilpiridin-2-karboksamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-6-metil-2-[5-(metilsulfonil)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[6-(2-metil-2H-tetrazol-5-il)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[6-(2-metil-2H-1,2,3-triazol-4-il)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[6-(5-metil-1,3,4-oksadiazol-2-il)piridin-3-il]benzonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[5-(1,3-oksazol-2-il)piridin-3-il]benzonitril;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-cijano-2-etoksi-5-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-[3-(metoksimetil)azetidin-1-il]benzonitril;
1-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-6-cijano-2-etoksi-fenil}azetidin-3-karbonitril;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-3-etoksi-6-metil-2-(1-metil-1H-pirazol-4-il)benzonitril; i
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-cijano-2-metoksi-5-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih spojeva; ili
c) izabran iz grupe koju čine:
5-(3-{1-[4-amino-5-okso-6-(1H-pirazol-4-il)pirido[2,3-d]pirimidin-8(5H)-il]etil}-5-kloro-2-metoksi-6-metilfenil)-N,N-dimetilpiridin-2-karboksamid; i
5-{3-[1-(4-amino-6-metil-5-oksopirido[2,3-d]pirimidin-8(5H)-il)etil]-5-kloro-2-metoksi-6-metilfenil}-N,N-dimetilpiridin-2-karboksamid;
ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih spojeva.
[image]
25. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 24 ili njegova farmaceutski prihvatljiva sol, naznačen time, što ugljik obilježen zvjezdicom u formuli I:
[image]
označava kiralni ugljik, a navedeni spoj ili navedena sol predstavljaju (S)-enantiomer.
26. Spoj iz patentnog zahtjeva 1, formule VII:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time, što:
G označava NH, n označava 1, a V označava O; ili
G označava NH, n označava 0 i V označava O ili CH2 grupu; ili
G označava O, n označava 0 i V označava NH;
X označava CR9 ili N;
W označava CR7 ili N;
Y označava CR8, CR8a ili N;
Z označava kemijsku vezu ili C(= O);
pod uvjetom da -W=Y-Z- označava -CR7=CR8, -N=CR8-, -CR7=CR8a-C(=O)-, -N=CR8a-C(=O)- ili -CR7=NC(=O)-;
R1 označava C1-3 alkil grupu;
R2 označava halogenu, C1-6 alkil, C1-6 alkoksi, C1-6 haloalkil, C1-6 haloalkoksi, fenil ili 5-6-članu heteroaril grupu; i naznačen je time, što svaka od navedenih fenil i 5-6-članih heteroaril grupa može biti supstituirana sa 1, 2, 3 ili 4 supstituenta nezavisno izabrana iz grupe koju čine halogena, OH, CN, C1-4 alkil, C1-4 alkoksi i C1-4 haloalkoksi grupa;
R4 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R5 označava halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, C1-4 haloalkoksi ili ciklopropil grupu;
R6 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R7 označava H ili C1-4 alkil grupu;
R8 označava H, halogenu, -OH, -CN, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, Cy2, -(C1-3 alkilen)-Cy2, ORa2, SRa2, C(=O)Rb2, C(=O)NRc2Rd2, C(=O)ORa2, OC(=O)Rb2, OC(=O)NRc2 Rd2, NRc2Rd2, NRc2C(=O)Rb2, NRc2 C(=O)ORb2, NRc2C(=O)NRc2Rd2, C(=NRe)Rb2, C(=NRe)NRc2Rd2, NRc2C(=NRe)NRc2Rd2, NRc2S(=O)Rb2, NRc2S(=O)2NRc2Rd2, S(=O)Rb2, S(=O)2Rb2 ili S(=O)2NRc2Rd2 grupu; i pri čemu svaka od navedenih C1-6 alkil, C2-6 alkenil, C2-6 alkinil grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
R8a označava H, halogenu, -CN, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, Cy2, -(C1-3 alkilen)-Cy2, C(=O)Rb2, C(=O)NRc2Rd2, C(=O)ORa2, NRc2Rd2, NRc2C(=O)Rb2, NRC(=O)ORb2, NRc2(=O)NRc2R2d, NRc2S(=O)Rb2, NRc2S(=O)2NRc2Rd2, S(=O)Rb2, S(=O)2Rb2 ili S(=O)2NRc2 Rd2 grupu; i pri čemu svaka navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
R9 označava H, halogenu, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi ili C1-4 haloalkoksi grupu;
R10 označava H ili C1-4 alkil grupu;
svaki Re je nezavisno izabran iz grupe koju čine H, CN, OH, C1-4 alkil i C1-4 alkoksi grupa;
svaki Cy2 je nezavisno izabran iz grupe koju čine C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil, 5-6-člana heteroaril ili 9-10-člana biciklična heteroaril grupa, i pri čemu svaka navedena grupa može biti supstituirana sa 1, 2, 3 ili 4 nezavisno izabrane R11 grupe;
svaki Ra2, Rb2, Rc2 i Rd2 je nezavisno izabran iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa; i pri čemu svaka navedena C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4-7-člana heterocikloalkil, fenil i 5-6-člana heteroaril grupa može biti supstituirana sa 1, 2 ili 3 nezavisno izabrane R11 grupe;
ili Rc2 i Rd2 zajedno sa atomom N za koji su vezani obrazuju 4-, 5-, 6- ili 7-članu heterocikloalkil grupu koja može biti supstituirana sa -OH ili C1-3 alkil grupom; i
svaki R11 je nezavisno izabran iz grupe koju čine OH, NO 2, CN, halogena, C1-3 alkil, C2-3 alkenil, C2-3 alkinil, C1-3 haloalkil, cijano-C1-3 alkil, HO-C1-3 alkil, C1-3 alkoksi-C1-3 alkil, C3-7 cikloalkil, C1-3 alkoksi, C1-3 haloalkoksi, amino, C1-3 alkilamino, di(C1-3 alkil)amino, tio, C1-3 alkiltio, C1-3 alkilsulfinil, C1-3 alkilsulfonil, karbamil, C1-3alkilkarbamil, di(C 1-3 alkil)karbamil, karboksi, C1-3 alkilkarbonil, C1-4 alkoksikarbonil, C1-3 alkilkarbonilamino, C1-3 alkilsulfonilamino, aminosulfonil, C1-3alkilaminosulfonil, di(C1-3 alkil)aminosulfonil, aminosulfonilamino, C1-3 alkilaminosulfonilamino, di(C1-3 alkil)aminosulfonilamino, aminokarbonilamino, C1-3 alkilamino-karbonilamino i di(C1-3 alkil)aminokarbonilamino grupa.
27. Spoj iz patentnog zahtjeva 26:
[image]
a) formule VIIA:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
[image]
b) formule VIIb:
[image]
ili njegova farmaceutski prihvatljiva sol.
28. Spoj iz patentnog zahtjeva 26 ili 27, ili njegova farmaceutski prihvatljiva sol, naznačen time, što:
a) G označava NH;
n označava 0;
V označava O;
R2 označava C1-3 alkoksi grupu;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu grupu; i
R6 označava H; ili
b) G označava NH;
n označava 0;
V označava CH2grupu;
R2 označava C1-3 alkoksi grupu;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu grupu; i
R6 označava H; ili
c) G označava NH;
n označava 1;
V označava O;
R2 označava C1-3 alkoksi grupu;
R4 označava halogenu, CN ili C1-4 alkil grupu;
R5 označava halogenu grupu; i
R6 označava H; ili
d) G označava O;
n označava 0;
V označava NH;
R2 označava C1-3 alkoksi grupu;
R4 označava halogenu grupu;
R5 označava halogenu grupu; i
R6 označava H.
29. Spoj iz patentnog zahtjeva 26, izabran iz grupe koju čine:
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-metilfenil}pirolidin-2-on;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(2-okso-1,3-oksazolidin-5-il)benzonitril;
6-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}morfolin-3-on;
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-metoksi-6-metilfenil}-1,3-oksazolidin-2-on;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(5-oksopirolidin-3-il)benzonitril;
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}-1,3-oksazolidin-2-on; i
5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}-1,3-oksazolidin-2-on,
ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih spojeva.
[image]
30. Spoj iz bilo kojeg od patentnih zahtjeva od 26 do 29, ili njegova farmaceutski prihvatljiva sol, naznačen time, što ugljik obilježen zvjezdicom u formuli VII:
[image]
označava kiralni ugljik, a navedeni spoj ili navedena sol predstavljaju (S)-enantiomer.
31. Spoj iz patentnog zahtjeva 26, koji označava 4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
32. Spoj iz patentnog zahtjeva 31, koji označava (S)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
33. Spoj iz patentnog zahtjeva 31, koji označava (R)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
34. Spoj iz patentnog zahtjeva 31, koji označava (S)-4-(3-((R)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
35. Spoj iz patentnog zahtjeva 31, koji označava (R)-4-(3-((R)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
36. Spoj iz patentnog zahtjeva 26, koji označava 5-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}-1,3-oksazolidin-2-on ili njegovu farmaceutski prihvatljivu sol.
37. Farmaceutski pripravak koji sadrži spoj iz bilo kojeg od patentnih zahtjeva od 1 do 31 i 36, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedan farmaceutski prihvatljiv nosač.
38. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 31 i 36, ili njegova farmaceutski prihvatljiva sol, za upotrebu u inhibiciji aktivnosti PI3K kinaze.
39. Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 38, naznačen time, što:
a) PI3K je izabrana iz grupe koju čine PI3Kα, PI3Kβ, PI3Kδ i PI3Kγ; ili
b) PI3K sadrži mutaciju.
40. Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu prema bilo kojem od patentnih zahtjeva od 38 do 39, naznačen time, što je navedeni spoj selektivni inhibitor PI3Kδ u većoj meri nego što predstavlja inhibitora jedne ili više kinaza izabranih iz grupe koju čine PI3Kα, PI3Kβ i PI3Kγ.
41. Spoj, ili njegova farmaceutski prihvatljiva sol, iz bilo kojeg od patentnih zahtjeva od 1 do 31 i 36 za upotrebu u tretmanu oboljenja kod pacijenta, naznačenog time, što navedeno oboljenje prati abnormalna ekspresija ili aktivnost PI3K kinaze.
42. Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 41, naznačenu time, što navedeno oboljenje označava osteoartritis, restenozu, aterosklerozu, oboljenja kostiju, artritis, dijabetsku retinopatiju, psorijazu, benignu hipertrofiju prostate, inflamaciju, angiogenezu, pankreatitis, oboljenje bubrega, inflamatorno oboljenje creva, mijasteniju gravis, multiplu sklerozu ili Sjogrenov sindrom.
43. Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu u skladu sa bilo kojim od patentnih zahtjeva od 41 do 42, naznačenu time, što se primjenjuje više od jednog navedenog spoja.
44. Spoj, ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 43, naznačenu time, što se spoj primjenjuje u kombinaciji sa inhibitorom kinaze koji inhibira kinaze drugačije od PI3K kinaze.
45. Spoj, ili njegova farmaceutski prihvatljiva sol, iz bilo kojeg od patentnih zahtjeva od 1 do 31 i 36 za upotrebu u tretmanu oboljenja izabranih iz grupe koju čine oboljenja u čijoj je osnovi poremećaj imunog sistema, rak ili oboljenje pluća kod pacijenta.
46. Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeno oboljenje u čijoj je osnovi poremećaj imunog sistema označava reumatoidni artritis, alergiju, astmu, glomerulonefritis, lupus ili inflamaciju koja prati bilo koje od prethodno navedenih oboljenja.
47. Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeni rak označava rak dojke, prostate, debelog creva, endometrija, mozga, mokraćnog mjehura, kože, maternice, jajnika, pluća, pankreasa, bubrega, želuca ili kematološki rak.
48. Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeni rak označava rak dojke, prostate, debelog creva, endometrija, mozga, mokraćnog mjehura, kože, maternice, jajnika, pluća, pankreasa, bubrega, želuca ili kematološki kancer, naznačen time, što navedeni kematološki rak označava akutnu mijeloblasnu leukemiju, kroničnu mijeloidnu leukemiju ili B-stanični limfom.
49. Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeni rak označava difuzni B-krupnostanični limfom.
50. Spoj za upotrebu prema patentnom zahtjevu 45, naznačen time, što navedeno oboljenje pluća označava akutnu povredu pluća (ALI) ili sindrom respiratornog distresa odraslih (ARDS).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530866P | 2011-09-02 | 2011-09-02 | |
US201261594882P | 2012-02-03 | 2012-02-03 | |
US201261677445P | 2012-07-30 | 2012-07-30 | |
EP12775861.3A EP2751109B1 (en) | 2011-09-02 | 2012-08-31 | Heterocyclylamines as pi3k inhibitors |
PCT/US2012/053398 WO2013033569A1 (en) | 2011-09-02 | 2012-08-31 | Heterocyclylamines as pi3k inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170285T1 true HRP20170285T1 (hr) | 2017-04-21 |
Family
ID=47071429
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170285TT HRP20170285T1 (hr) | 2011-09-02 | 2017-02-21 | Heterociklilamini kao inhibitori pi3k |
HRP20190824TT HRP20190824T1 (hr) | 2011-09-02 | 2019-05-02 | Heterociklilamini kao inhibitori pi3k |
HRP20210627TT HRP20210627T1 (hr) | 2011-09-02 | 2021-04-21 | Heterociklilamini kao inhibitori pi3k |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190824TT HRP20190824T1 (hr) | 2011-09-02 | 2019-05-02 | Heterociklilamini kao inhibitori pi3k |
HRP20210627TT HRP20210627T1 (hr) | 2011-09-02 | 2021-04-21 | Heterociklilamini kao inhibitori pi3k |
Country Status (37)
Country | Link |
---|---|
US (8) | US9199982B2 (hr) |
EP (4) | EP3888657A1 (hr) |
JP (8) | JP6067709B2 (hr) |
KR (7) | KR102507287B1 (hr) |
CN (1) | CN106986867B (hr) |
AR (1) | AR087760A1 (hr) |
AU (5) | AU2012301721B2 (hr) |
BR (2) | BR122019020716B1 (hr) |
CA (1) | CA2846652C (hr) |
CL (1) | CL2014000517A1 (hr) |
CO (1) | CO6910199A2 (hr) |
CR (2) | CR20180293A (hr) |
CY (3) | CY1118679T1 (hr) |
DK (3) | DK2751109T3 (hr) |
EA (2) | EA028890B1 (hr) |
EC (1) | ECSP14013274A (hr) |
ES (3) | ES2722524T3 (hr) |
HK (1) | HK1199644A1 (hr) |
HR (3) | HRP20170285T1 (hr) |
HU (3) | HUE043703T2 (hr) |
IL (6) | IL299533A (hr) |
LT (3) | LT3513793T (hr) |
ME (2) | ME02595B (hr) |
MX (2) | MX2020004502A (hr) |
MY (1) | MY179332A (hr) |
NZ (1) | NZ769326A (hr) |
PE (2) | PE20181272A1 (hr) |
PH (2) | PH12017501766A1 (hr) |
PL (3) | PL3196202T3 (hr) |
PT (3) | PT3513793T (hr) |
RS (3) | RS55737B1 (hr) |
SG (3) | SG11201400232WA (hr) |
SI (3) | SI3196202T1 (hr) |
SM (1) | SMT201700111B (hr) |
TW (6) | TWI648277B (hr) |
WO (1) | WO2013033569A1 (hr) |
ZA (1) | ZA201904877B (hr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
TW201130842A (en) | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | PI3Kδ阻害剤としての縮合誘導体 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
HUE043703T2 (hu) * | 2011-09-02 | 2019-09-30 | Incyte Holdings Corp | Heterociklusos aminok PI3K inhibitorokként |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
KR20200017549A (ko) | 2012-06-04 | 2020-02-18 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
EA035391B1 (ru) | 2012-11-08 | 2020-06-05 | Ризен Фармасьютикалз Са | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
JP6554037B2 (ja) | 2013-01-15 | 2019-07-31 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物 |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
AU2014308703A1 (en) | 2013-08-23 | 2016-03-24 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors |
SG10201710436WA (en) | 2014-02-03 | 2018-01-30 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
US9394236B2 (en) * | 2014-02-03 | 2016-07-19 | Quadriga Biosciences, Inc. | β-substituted γ-amino acids and analogs as chemotherapeutic agents |
ES2829914T3 (es) * | 2014-04-08 | 2021-06-02 | Incyte Corp | Tratamiento de enfermedades malignas de células B mediante una combinación de inhibidor de JAK y PI3K |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
TWI764392B (zh) | 2015-02-27 | 2022-05-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
NZ734446A (en) | 2015-03-03 | 2022-12-23 | Pharmacyclics Llc | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor |
JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
WO2017024009A1 (en) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
TWI734699B (zh) * | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
AR107293A1 (es) | 2016-01-05 | 2018-04-18 | Incyte Corp | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g |
CA3019145A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
LT3687996T (lt) | 2017-09-27 | 2022-01-10 | Incyte Corporation | Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai |
WO2019079469A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
EP3801533A1 (en) | 2018-06-01 | 2021-04-14 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
PE20211805A1 (es) | 2018-06-29 | 2021-09-14 | Incyte Corp | Formulaciones de un inhibidor de axl/mer |
MX2021002551A (es) | 2018-09-05 | 2021-07-15 | Incyte Corp | Formas cristalinas de inhibidor de fosfoinositida 3-cinasa (pi3k). |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
TW202114681A (zh) | 2019-07-02 | 2021-04-16 | 美商eFFECTOR醫療公司 | 轉譯抑制劑及其用途 |
TW202140487A (zh) * | 2020-02-06 | 2021-11-01 | 美商英塞特公司 | Pi3k抑制劑之鹽及固體形式以及其製備方法 |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115762A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
Family Cites Families (293)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169967A (en) | 1957-11-14 | 1965-02-16 | Ciba Geigy Corp | Methyl o-lower alkanoyl-reserpates |
US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
DE1770420U (de) | 1958-02-27 | 1958-07-17 | Tara Union G M B H | Blumentopf aus kunststoff. |
US3506643A (en) | 1966-12-09 | 1970-04-14 | Max Thiel | N**6-aralkyl-adenosine derivatives |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
US3814251A (en) | 1972-08-09 | 1974-06-04 | Sperry Rand Corp | Power transmission |
US3962443A (en) | 1972-08-14 | 1976-06-08 | Dainippon Pharmaceutical Co., Ltd. | Antibacterial pharmaceutical compositions and processes for preparation thereof |
DE2248232A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine |
AR204003A1 (es) | 1973-04-03 | 1975-11-12 | Dainippon Pharmaceutical Co | Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables |
US3936454A (en) | 1973-08-14 | 1976-02-03 | Warner-Lambert Company | 5-Amino-4-chloro-6-(substituted amino)-pyrimidines |
US3862189A (en) | 1973-08-14 | 1975-01-21 | Warner Lambert Co | Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents |
DK3375A (hr) | 1974-01-25 | 1975-09-15 | Ciba Geigy Ag | |
JPS587626B2 (ja) | 1974-02-13 | 1983-02-10 | 大日本製薬株式会社 | ナフチリジン オヨビ キノリンユウドウタイノセイホウ |
JPS50111080U (hr) | 1974-02-21 | 1975-09-10 | ||
JPS5625234Y2 (hr) | 1976-01-17 | 1981-06-15 | ||
JPS5359663A (en) | 1976-11-09 | 1978-05-29 | Sumitomo Chem Co Ltd | 2-halogeno methyl indole derivatives and process for praparation of the same |
JPS52106897A (en) | 1977-01-10 | 1977-09-07 | Dainippon Pharmaceut Co Ltd | Synthesis of piperazine derivatives |
JPS5392767A (en) | 1977-01-27 | 1978-08-15 | Sumitomo Chem Co Ltd | Preparation of 2-phthalimidomethylindole derivatives |
JPS5625234A (en) | 1979-08-02 | 1981-03-11 | Hitachi Denshi Ltd | Dropout display system |
JPS56123981U (hr) | 1980-02-20 | 1981-09-21 | ||
JPS56123981A (en) | 1981-02-23 | 1981-09-29 | Dainippon Pharmaceut Co Ltd | Preparation of 1,4-disubstituted piperazine |
JPS5883698A (ja) | 1981-11-13 | 1983-05-19 | Takeda Chem Ind Ltd | キノン化合物およびその製造法 |
JPS5883698U (ja) | 1981-11-27 | 1983-06-06 | 石川島播磨重工業株式会社 | 熱交換器 |
JPS58162949A (ja) | 1982-03-20 | 1983-09-27 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS60140373U (ja) | 1984-02-28 | 1985-09-17 | 東洋ハ−ネス株式会社 | ワイヤハ−ネスのア−ス構造 |
JPS6190153A (ja) | 1984-10-09 | 1986-05-08 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPS62103640A (ja) | 1985-07-18 | 1987-05-14 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS62103640U (hr) | 1985-12-18 | 1987-07-02 | ||
JPH07119970B2 (ja) | 1986-04-18 | 1995-12-20 | 富士写真フイルム株式会社 | 画像形成方法 |
JPS6310746A (ja) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
CA1324609C (en) | 1986-07-30 | 1993-11-23 | Eastman Kodak Company | Photographic element and process |
US4861701A (en) | 1987-10-05 | 1989-08-29 | Eastman Kodak Company | Photographic element and process comprising a compound which comprises two timing groups in sequence |
AT388372B (de) | 1987-10-08 | 1989-06-12 | Tanabe Seiyaku Co | Neue naphthalinderivate und sie enthaltende pharmazeutika |
JPH01250316A (ja) | 1987-12-28 | 1989-10-05 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
HU208124B (en) | 1990-04-25 | 1993-08-30 | Nissan Chemical Ind Ltd | Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient |
SU1712359A1 (ru) | 1990-05-07 | 1992-02-15 | Уфимский Нефтяной Институт | Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR |
EP0464612B1 (en) | 1990-06-28 | 1998-05-13 | Fuji Photo Film Co., Ltd. | Silver halide photographic materials |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU1625192A (en) | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
JP3108483B2 (ja) | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
HUT64064A (en) | 1992-02-13 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
AU3933493A (en) | 1992-04-24 | 1993-11-29 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal aminopyrimidines |
TW229140B (hr) | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
FR2714907B1 (fr) | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
US6342501B1 (en) | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
JPH0987282A (ja) | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
JPH1025294A (ja) | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
DE69731823T2 (de) | 1996-07-03 | 2005-12-15 | Sumitomo Pharmaceuticals Co., Ltd. | Neue purinderivate |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
JPH10231297A (ja) | 1997-02-20 | 1998-09-02 | Japan Energy Corp | 新規なアデニン−1−n−オキシド誘導体およびその医薬用途 |
ES2222614T3 (es) | 1997-11-12 | 2005-02-01 | Mitsubishi Chemical Corporation | Derivados de purina y medicina que los contiene como ingrediente activo. |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
AU3297099A (en) | 1998-02-25 | 1999-09-15 | Genetics Institute Inc. | Inhibitors of phospholipase a2 |
SK12742000A3 (sk) | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
BR9911017A (pt) | 1998-05-04 | 2001-02-06 | Asta Medica Ag | Derivados de indol e seu emprego para o tratamento de doenças malignas e outras, que se baseiam na proliferação de células patológicas |
ATE482945T1 (de) | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
JP3997651B2 (ja) | 1998-06-24 | 2007-10-24 | コニカミノルタホールディングス株式会社 | 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液 |
AU5620299A (en) | 1998-08-11 | 2000-03-06 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
CA2341506A1 (en) | 1998-08-25 | 2000-03-02 | The Uab Research Foundation | Inhibitors of bacterial nad synthetase |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
RU2001124352A (ru) | 1999-02-01 | 2004-02-20 | Си Ви Терапьютикс, Инк. (Us) | Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
JP2000281654A (ja) | 1999-03-26 | 2000-10-10 | Tanabe Seiyaku Co Ltd | イソキノリン誘導体 |
DE19932571A1 (de) | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
JP2001151771A (ja) | 1999-09-10 | 2001-06-05 | Kyowa Hakko Kogyo Co Ltd | 含窒素芳香族複素環誘導体 |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
EP1138328A1 (en) | 2000-03-29 | 2001-10-04 | Eli Lilly And Company Limited | Naphthalene derivatives as CNS drugs |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
CN1331340A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸 |
KR100748294B1 (ko) | 2000-07-05 | 2007-08-09 | 아스텔라스세이야쿠 가부시키가이샤 | 프로판-1,3-디온 유도체 |
FR2814073B1 (fr) | 2000-09-21 | 2005-06-24 | Yang Ji Chemical Company Ltd | Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition |
DOP2002000334A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
EP1375486B1 (en) | 2001-03-01 | 2008-10-15 | Shionogi & Co., Ltd. | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
EP1372643A1 (en) | 2001-03-30 | 2004-01-02 | Smithkline Beecham Corporation | Pyrazolopyridines, process for their preparation and use as therapeutic compounds |
JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
WO2002088124A2 (en) | 2001-04-27 | 2002-11-07 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
CZ294535B6 (cs) | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
IL160915A0 (en) | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
JP2005504808A (ja) | 2001-09-26 | 2005-02-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 抗糖尿病薬としての1,6−ナフチリジン誘導体 |
AU2002341920A1 (en) | 2001-10-02 | 2003-04-14 | Smithkline Beecham Corporation | Chemical compounds |
TWI302836B (en) | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
CA2465090C (en) | 2001-11-09 | 2010-02-02 | Enzon, Inc. | Polymeric thiol-linked prodrugs employing benzyl elimination systems |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
DE60231439D1 (de) | 2001-12-06 | 2009-04-16 | Merck & Co Inc | Mitotische kinesinhemmer |
ES2291543T3 (es) | 2001-12-06 | 2008-03-01 | MERCK & CO., INC. | Inhibicion de kinesina mitotica. |
TW200301135A (en) | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
CA2476162A1 (en) | 2002-02-13 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
US20050049267A1 (en) | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
ES2291628T3 (es) | 2002-04-03 | 2008-03-01 | Bristol-Myers Squibb Company | Compuestos triciclicos a base de tiofeno y composiciones farmaceuticas que comprenden dichos compuestos. |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
EP2045242A1 (en) | 2002-08-13 | 2009-04-08 | Shionogi&Co., Ltd. | Heterocyclic compounds having inhibitory activity against HIV integrase |
JP4190232B2 (ja) | 2002-08-26 | 2008-12-03 | 富士通株式会社 | 機械研磨を行う方法 |
EP1550662B1 (en) | 2002-09-27 | 2012-07-04 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
EP1568688B1 (en) | 2002-11-25 | 2011-08-31 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP4500689B2 (ja) | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
CZ294538B6 (cs) | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
RU2233842C1 (ru) | 2003-01-13 | 2004-08-10 | Петров Владимир Иванович | Производные пурина, обладающие противовирусной активностью |
AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
SE0300908D0 (sv) | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
CA2524376A1 (en) | 2003-05-05 | 2004-12-16 | Neurogen Corporation | Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands |
CN1809563A (zh) | 2003-06-20 | 2006-07-26 | 希龙公司 | 吡啶并[1,2-a]嘧啶-4-酮化合物用作抗癌药 |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
JP4570015B2 (ja) | 2003-07-14 | 2010-10-27 | クミアイ化学工業株式会社 | 2−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤 |
US20050124637A1 (en) | 2003-08-15 | 2005-06-09 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
US7709476B2 (en) | 2003-09-23 | 2010-05-04 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
US20060025383A1 (en) | 2004-02-03 | 2006-02-02 | Neil Wishart | Aminobenzoxazoles as therapeutic agents |
EP1717238A4 (en) | 2004-02-16 | 2008-03-05 | Daiichi Seiyaku Co | FUNGICIDES HETEROCYCLIC COMPOUNDS |
CN1560035A (zh) | 2004-03-12 | 2005-01-05 | 沈阳药科大学 | 5-羟基吲哚-3-羧酸脂类衍生物 |
WO2005091857A2 (en) | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
JPWO2005092892A1 (ja) | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | 8−オキソアデニン化合物 |
EP1740587A4 (en) | 2004-04-02 | 2009-07-15 | Adenosine Therapeutics Llc | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS |
EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
CN101023082A (zh) | 2004-07-22 | 2007-08-22 | 阿斯利康(瑞典)有限公司 | 用于治疗和预防癌症的稠合嘧啶酮类 |
JP2008509977A (ja) | 2004-08-18 | 2008-04-03 | アストラゼネカ アクチボラグ | 癌の処置及び予防における選択された縮合複素環の鏡像異性体及びその使用 |
DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP2275412A1 (en) | 2004-10-19 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Indole and benzimidazole derivatives |
WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
AU2006214190A1 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
DE602006015658D1 (de) | 2005-06-27 | 2010-09-02 | Amgen Inc | Entzündungshemmende arylnitrilverbindungen |
FR2889192A1 (fr) | 2005-07-27 | 2007-02-02 | Cytomics Systems Sa | Composes antifongiques, compositions contenant ces composes et leurs utilisations |
US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
EP1951684B1 (en) | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
WO2007059108A2 (en) | 2005-11-10 | 2007-05-24 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
ES2611588T3 (es) | 2005-12-13 | 2017-05-09 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
EP1984375A2 (en) | 2006-01-25 | 2008-10-29 | Smithkline Beecham Corporation | Chemical compounds |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
US20090069304A1 (en) | 2006-03-03 | 2009-03-12 | Shionogi & Co., Ltd. | Mmp-13 selective inhibitor |
AU2007245129A1 (en) | 2006-03-29 | 2007-11-08 | Foldrx Pharmaceuticals, Inc. | Inhibition of alpha-synuclein toxicity |
WO2008127226A2 (en) * | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | P13 kinase antagonists |
DE102006029074A1 (de) * | 2006-06-22 | 2007-12-27 | Friedrich-Schiller-Universität Jena | 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe |
EP2037905B1 (en) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
WO2008005303A2 (en) | 2006-06-30 | 2008-01-10 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
US20080009508A1 (en) | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
CA2656855A1 (en) | 2006-07-12 | 2008-01-17 | Christoph Luthy | Triazolopyridine derivatives as herbicides |
JP4450857B2 (ja) | 2006-08-08 | 2010-04-14 | 中外製薬株式会社 | Pi3k阻害剤としてのピリミジン誘導体およびその用途 |
CA2662074A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
EP1972631A1 (en) | 2007-03-23 | 2008-09-24 | Novartis AG | Imidazopyridazines as PI3K lipid kinase inhibitors |
WO2008055013A2 (en) | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
EP2097422A4 (en) | 2006-11-13 | 2010-04-14 | Lilly Co Eli | THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS |
ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
EP2134713A2 (en) | 2006-12-20 | 2009-12-23 | Schering Corporation | Novel jnk inhibitors |
EP2125827B1 (en) | 2006-12-29 | 2010-11-03 | F. Hoffmann-La Roche AG | Azaspiro derivatives |
WO2008097991A1 (en) | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
US20090047246A1 (en) | 2007-02-12 | 2009-02-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
TW200902018A (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
CA2680783C (en) | 2007-03-23 | 2012-04-24 | Amgen Inc. | Heterocyclic compounds and their uses |
RS54706B1 (en) | 2007-03-23 | 2016-08-31 | Amgen Inc. | HETEROCYCLIC UNITS AND THEIR USES |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US8088385B2 (en) | 2007-06-18 | 2012-01-03 | University Of Louisville Research Foundation Inc. | PFKB3 inhibitor for the treatment of a proliferative cancer |
AU2008271127C1 (en) | 2007-06-29 | 2014-04-17 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of Toll-like receptor 7 |
US20090053192A1 (en) | 2007-08-10 | 2009-02-26 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
JP2009076865A (ja) | 2007-08-29 | 2009-04-09 | Fujifilm Corp | 有機電界発光素子 |
WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
JP2009080233A (ja) | 2007-09-26 | 2009-04-16 | Kyocera Mita Corp | 電子写真感光体 |
CZ300774B6 (cs) | 2007-10-05 | 2009-08-05 | Univerzita Palackého | Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny |
US20100331297A1 (en) | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
WO2009063235A1 (en) | 2007-11-13 | 2009-05-22 | Astrazeneca Ab | Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018 |
JP2009120686A (ja) | 2007-11-14 | 2009-06-04 | Toyo Ink Mfg Co Ltd | 光重合開始剤、重合性組成物、および重合物の製造方法。 |
WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
WO2009081105A2 (en) | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
CN101945871A (zh) | 2007-12-21 | 2011-01-12 | 惠氏有限责任公司 | 咪唑并[1,2-a]吡啶化合物 |
BRPI0722222A2 (pt) | 2007-12-28 | 2015-06-16 | Topharman Shangai Co Ltd | N-{1-[3-(2-etóxi-5-(4-etilpiperazinil)sulfonilfenil)-4,5-di hidro-5-oxo-1,2,4-triazina-6-il]etil}butiramida, seu método de preparo e seu uso |
US7960397B2 (en) | 2007-12-28 | 2011-06-14 | Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions |
US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2247596A2 (en) | 2008-01-11 | 2010-11-10 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
EP2252616B1 (en) | 2008-01-30 | 2014-07-23 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
US20110105457A1 (en) | 2008-04-18 | 2011-05-05 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on pi3k |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
WO2009140215A2 (en) | 2008-05-11 | 2009-11-19 | Geraghty, Erin | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
WO2009151972A1 (en) | 2008-05-28 | 2009-12-17 | , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command | Small molecule inhibitors of botulinum neurotoxins |
KR20110026481A (ko) | 2008-06-20 | 2011-03-15 | 메타볼렉스, 인코포레이티드 | 아릴 gpr119 작동약 및 이의 용도 |
US8026271B2 (en) | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
CA3092449A1 (en) | 2008-11-13 | 2010-05-20 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
TWI469979B (zh) | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
WO2010083444A1 (en) | 2009-01-15 | 2010-07-22 | Anvyl, Llc | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
ES2598358T3 (es) | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
EP2414044A1 (en) | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted indolo-piperidine compounds |
WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
WO2010151740A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
AU2010266064A1 (en) | 2009-06-25 | 2012-01-19 | Amgen Inc. | 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors |
EP3241554B1 (en) | 2009-06-29 | 2020-01-29 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
AR077974A1 (es) | 2009-08-28 | 2011-10-05 | Takeda Pharmaceutical | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR20120102601A (ko) | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
US8507507B2 (en) | 2009-10-22 | 2013-08-13 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
MY173795A (en) * | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
AU2010317501B2 (en) | 2009-11-10 | 2013-06-06 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
WO2011058111A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Aminopurine derivatives as kinase inhibitors |
EP2499126B1 (en) | 2009-11-12 | 2015-01-07 | UCB Pharma, S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
CN102812033B (zh) | 2009-12-10 | 2015-11-25 | 中国医学科学院药物研究所 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
TW201130842A (en) | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
CA2784566A1 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Heterocyclic compounds and their uses |
BR112012017126A2 (pt) * | 2009-12-23 | 2017-10-31 | Palau Pharma Sa | derivados de aminoalquilpirimidina como antagonistas de receptor de h4 de histamina |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
PL2521452T3 (pl) | 2010-01-07 | 2015-05-29 | Dow Agrosciences Llc | Tiazolo[5,4-d]pirymidyny i ich zastosowanie jako agrochemikaliów |
US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
NZ602313A (en) | 2010-03-10 | 2014-08-29 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
EA201290888A1 (ru) | 2010-03-22 | 2013-04-30 | Гленмарк Фармасьютикалс С.А. | Фармацевтическая композиция, содержащая производное пиримидинона |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | PI3Kδ阻害剤としての縮合誘導体 |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
AU2011265258A1 (en) | 2010-06-11 | 2013-01-10 | Calistoga Pharmaceuticals, Inc. | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
CA2803009A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
AU2011271460B2 (en) | 2010-07-01 | 2014-02-06 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of P13K activity |
EP2588469A1 (en) | 2010-07-02 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
JP2013540758A (ja) | 2010-09-24 | 2013-11-07 | ギリアード カリストガ エルエルシー | Pi3k阻害化合物のアトロプ異性体 |
US20140031355A1 (en) | 2010-11-04 | 2014-01-30 | Amgen Inc. | Heterocyclic compounds and their uses |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2640715A1 (en) | 2010-11-17 | 2013-09-25 | Amgen Inc. | Quinoline derivatives as pik3 inhibitors |
CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
ES2553610T3 (es) | 2010-12-14 | 2015-12-10 | Electrophoretics Limited | Inhibidores de la caseína cinasa 1 delta (CK1delta) |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
MX2013007261A (es) | 2010-12-23 | 2013-11-04 | Amgen Inc | Compuestos heterociclicos y sus usos. |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
ES2734878T3 (es) | 2011-02-01 | 2019-12-12 | Univ Illinois | Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
HUE043703T2 (hu) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corp | Heterociklusos aminok PI3K inhibitorokként |
CA2850763A1 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
HUE058914T2 (hu) | 2013-03-15 | 2022-09-28 | Janssen Pharmaceutica Nv | Gyógyszer elõállítására szolgáló eljárások és köztitermékek |
SI2997023T1 (sl) | 2013-05-17 | 2017-07-31 | Incyte Corporation | Bipirazolni derivati kot inhibitorji JAK |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
TWI764392B (zh) | 2015-02-27 | 2022-05-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2016183062A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
EP3801533A1 (en) | 2018-06-01 | 2021-04-14 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
-
2012
- 2012-08-31 HU HUE16199883A patent/HUE043703T2/hu unknown
- 2012-08-31 HU HUE18215449A patent/HUE053953T2/hu unknown
- 2012-08-31 SG SG11201400232WA patent/SG11201400232WA/en unknown
- 2012-08-31 TW TW106144503A patent/TWI648277B/zh active
- 2012-08-31 US US13/601,349 patent/US9199982B2/en active Active
- 2012-08-31 PT PT182154492T patent/PT3513793T/pt unknown
- 2012-08-31 CA CA2846652A patent/CA2846652C/en active Active
- 2012-08-31 SI SI201231554T patent/SI3196202T1/sl unknown
- 2012-08-31 MX MX2020004502A patent/MX2020004502A/es unknown
- 2012-08-31 SG SG10201912484RA patent/SG10201912484RA/en unknown
- 2012-08-31 KR KR1020227007113A patent/KR102507287B1/ko active IP Right Grant
- 2012-08-31 EA EA201490541A patent/EA028890B1/ru unknown
- 2012-08-31 SG SG10201601589QA patent/SG10201601589QA/en unknown
- 2012-08-31 CR CR20180293A patent/CR20180293A/es unknown
- 2012-08-31 TW TW108132191A patent/TWI717002B/zh active
- 2012-08-31 DK DK12775861.3T patent/DK2751109T3/en active
- 2012-08-31 KR KR1020237007424A patent/KR20230038593A/ko active Application Filing
- 2012-08-31 KR KR1020217013147A patent/KR102371532B1/ko active IP Right Grant
- 2012-08-31 BR BR122019020716-0A patent/BR122019020716B1/pt active IP Right Grant
- 2012-08-31 ME MEP-2017-15A patent/ME02595B/me unknown
- 2012-08-31 PE PE2018000759A patent/PE20181272A1/es unknown
- 2012-08-31 MX MX2014002360A patent/MX360262B/es active IP Right Grant
- 2012-08-31 TW TW107136772A patent/TWI673272B/zh active
- 2012-08-31 PT PT127758613T patent/PT2751109T/pt unknown
- 2012-08-31 PL PL16199883T patent/PL3196202T3/pl unknown
- 2012-08-31 RS RS20170191A patent/RS55737B1/sr unknown
- 2012-08-31 AU AU2012301721A patent/AU2012301721B2/en active Active
- 2012-08-31 JP JP2014528654A patent/JP6067709B2/ja active Active
- 2012-08-31 RS RS20210409A patent/RS61761B1/sr unknown
- 2012-08-31 BR BR112014004971-8A patent/BR112014004971B1/pt active IP Right Grant
- 2012-08-31 LT LTEP18215449.2T patent/LT3513793T/lt unknown
- 2012-08-31 RS RS20190445A patent/RS58817B1/sr unknown
- 2012-08-31 TW TW110100318A patent/TWI765515B/zh active
- 2012-08-31 ME MEP-2019-105A patent/ME03397B/me unknown
- 2012-08-31 PE PE2014000287A patent/PE20141726A1/es active IP Right Grant
- 2012-08-31 ES ES16199883T patent/ES2722524T3/es active Active
- 2012-08-31 PL PL18215449T patent/PL3513793T3/pl unknown
- 2012-08-31 WO PCT/US2012/053398 patent/WO2013033569A1/en active Application Filing
- 2012-08-31 TW TW105111882A patent/TWI619714B/zh active
- 2012-08-31 ES ES18215449T patent/ES2873001T3/es active Active
- 2012-08-31 NZ NZ769326A patent/NZ769326A/en unknown
- 2012-08-31 KR KR1020207018981A patent/KR102249236B1/ko active IP Right Grant
- 2012-08-31 DK DK16199883.6T patent/DK3196202T3/da active
- 2012-08-31 LT LTEP16199883.6T patent/LT3196202T/lt unknown
- 2012-08-31 AR ARP120103232A patent/AR087760A1/es active IP Right Grant
- 2012-08-31 SI SI201231917T patent/SI3513793T1/sl unknown
- 2012-08-31 PT PT16199883T patent/PT3196202T/pt unknown
- 2012-08-31 EP EP21158471.9A patent/EP3888657A1/en active Pending
- 2012-08-31 ES ES12775861.3T patent/ES2616477T3/es active Active
- 2012-08-31 HU HUE12775861A patent/HUE030869T2/en unknown
- 2012-08-31 KR KR1020197028988A patent/KR102131612B1/ko active IP Right Grant
- 2012-08-31 IL IL299533A patent/IL299533A/en unknown
- 2012-08-31 EP EP18215449.2A patent/EP3513793B1/en active Active
- 2012-08-31 MY MYPI2014000585A patent/MY179332A/en unknown
- 2012-08-31 EP EP16199883.6A patent/EP3196202B1/en active Active
- 2012-08-31 TW TW101131936A patent/TWI543980B/zh active
- 2012-08-31 EP EP12775861.3A patent/EP2751109B1/en active Active
- 2012-08-31 LT LTEP12775861.3T patent/LT2751109T/lt unknown
- 2012-08-31 CN CN201610946568.1A patent/CN106986867B/zh active Active
- 2012-08-31 EA EA201791929A patent/EA033646B1/ru unknown
- 2012-08-31 KR KR1020147008462A patent/KR101982475B1/ko active IP Right Grant
- 2012-08-31 PL PL12775861T patent/PL2751109T3/pl unknown
- 2012-08-31 DK DK18215449.2T patent/DK3513793T3/da active
- 2012-08-31 SI SI201230871A patent/SI2751109T1/sl unknown
- 2012-08-31 KR KR1020197011240A patent/KR102030609B1/ko active IP Right Grant
-
2014
- 2014-02-27 IL IL231239A patent/IL231239A/en active IP Right Grant
- 2014-02-28 CL CL2014000517A patent/CL2014000517A1/es unknown
- 2014-03-04 CR CR20140111A patent/CR20140111A/es unknown
- 2014-03-18 CO CO14058225A patent/CO6910199A2/es active IP Right Grant
- 2014-03-28 EC ECSP14013274 patent/ECSP14013274A/es unknown
-
2015
- 2015-01-06 HK HK15100068.0A patent/HK1199644A1/xx unknown
- 2015-10-01 US US14/872,918 patent/US9707233B2/en active Active
- 2015-10-01 US US14/872,881 patent/US9730939B2/en active Active
-
2016
- 2016-09-29 JP JP2016191928A patent/JP6263591B2/ja active Active
- 2016-12-21 JP JP2016248325A patent/JP6266743B2/ja active Active
-
2017
- 2017-02-16 SM SM201700111T patent/SMT201700111B/it unknown
- 2017-02-21 HR HRP20170285TT patent/HRP20170285T1/hr unknown
- 2017-02-24 CY CY20171100264T patent/CY1118679T1/el unknown
- 2017-05-09 IL IL252184A patent/IL252184B/en active IP Right Grant
- 2017-07-20 AU AU2017206260A patent/AU2017206260B2/en active Active
- 2017-08-10 US US15/673,529 patent/US10092570B2/en active Active
- 2017-09-26 PH PH12017501766A patent/PH12017501766A1/en unknown
- 2017-12-20 JP JP2017243651A patent/JP6427257B2/ja active Active
-
2018
- 2018-02-18 IL IL257576A patent/IL257576B/en active IP Right Grant
- 2018-08-24 US US16/112,160 patent/US10376513B2/en active Active
- 2018-10-26 JP JP2018201775A patent/JP6574039B2/ja active Active
-
2019
- 2019-02-28 AU AU2019201423A patent/AU2019201423B2/en active Active
- 2019-05-02 HR HRP20190824TT patent/HRP20190824T1/hr unknown
- 2019-05-21 CY CY20191100541T patent/CY1121651T1/el unknown
- 2019-06-19 US US16/446,098 patent/US10646492B2/en active Active
- 2019-07-25 ZA ZA2019/04877A patent/ZA201904877B/en unknown
- 2019-08-14 JP JP2019148821A patent/JP7038685B2/ja active Active
- 2019-09-27 PH PH12019502246A patent/PH12019502246A1/en unknown
-
2020
- 2020-03-05 IL IL273079A patent/IL273079B/en unknown
- 2020-03-05 IL IL284539A patent/IL284539B2/en unknown
- 2020-03-24 US US16/828,315 patent/US11433071B2/en active Active
-
2021
- 2021-01-18 AU AU2021200266A patent/AU2021200266B2/en active Active
- 2021-04-21 HR HRP20210627TT patent/HRP20210627T1/hr unknown
- 2021-05-19 CY CY20211100435T patent/CY1124168T1/el unknown
- 2021-12-24 JP JP2021210253A patent/JP7384891B2/ja active Active
-
2022
- 2022-07-18 US US17/866,942 patent/US11819505B2/en active Active
- 2022-12-22 AU AU2022291574A patent/AU2022291574A1/en active Pending
-
2023
- 2023-11-09 JP JP2023191694A patent/JP2023184724A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170285T1 (hr) | Heterociklilamini kao inhibitori pi3k | |
JP2014527959A5 (hr) | ||
RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
CA3007412C (en) | The use of 1,4-disubstituted pyridazine compounds to treat huntington's disease | |
US20240116930A1 (en) | P2x7 modulators | |
CA2900855C (en) | Aminopyrimidinyl compounds | |
JP2017052805A5 (hr) | ||
JP2018044008A5 (hr) | ||
JP2018522859A5 (hr) | ||
HRP20160326T1 (hr) | Derivati piperidin-4-il azetidina kao inhibitori jak1 | |
US20110053897A1 (en) | Compounds and compositions as syk kinase inhibitors | |
JP2015537010A5 (hr) | ||
RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
RU2015122895A (ru) | Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта | |
JP2019519484A5 (hr) | ||
JP2021506941A5 (hr) | ||
JP2018500376A5 (hr) | ||
CN116003441A (zh) | 杂芳类衍生物调节剂、其制备方法和应用 | |
JP2018522046A5 (hr) | ||
JP2015522002A5 (hr) | ||
RU2015129538A (ru) | Замещенные имидазопиридины в качестве ингибиторов hdm2 | |
WO2020150626A1 (en) | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors | |
JP2014521711A5 (hr) | ||
JP2015527399A5 (hr) | ||
JPWO2020005873A5 (hr) |